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 Due to the increasing prevalence of obesity and diabetes among children and 
adults worldwide, it is imperative to identify dietary strategies that promote weight 
control. One potential anti-obesity compound is conjugated linoleic acid (CLA), sold 
worldwide for weight loss. However, the safety and efficacy of this supplement remains 
questionable.  
Current research shows that, in addition to reducing fat mass, trans-10,cis-12 
(10,12) CLA supplementation in animals and some humans leads to insulin resistance, 
hyperlipidemia, or fatty liver. In vitro studies suggest that 10,12 CLA causes 
inflammation in primary cultures of human adipocytes by increasing mitogen activated 
extracellular kinase/extracellular signal-related kinase (MEK/ERK) and nuclear factor 
kappa B (NFκB) signaling, which impairs glucose and fatty acid uptake and utilization. 
However, the link between inflammatory signaling in primary cultures of human 
adipocytes and CLA-mediated delipidation has not been fully characterized. 
Additionally, the particular cell type (i.e., preadipoyctes vs. adipocytes) responsible for 
10,12 CLA-mediated inflammation and insulin resistance in white adipose tissue is 
unknown. Therefore, the objective of this work was to determine the cell type responsible 
for 10,12 CLA-mediated inflammation and insulin resistance in cultures of newly 
differentiated human adipocytes (Aim 1), and to identify the specific upstream  
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mechanisms involved (Aim 2). To examine Aim 1, inflammatory gene expression and 
protein secretion, prostaglandin secretion, or mitogen-activated protein kinase (MAPK) 
and cJun phosphorylation was measured in adipocytes vs. preadipocytes in four distinct 
cell culture models. To examine Aim 2, chemical inhibitors were employed to determine 
the role of protein kinases, including the MAPK cJun N-terminal kinase (JNK) and 
diacylglycerol kinases (DGKs) in 10,12 CLA-mediated inflammatory signaling and 
insulin resistance in newly differentiated primary human adipocytes. Collectively, results 
from this project reveal that 10,12 CLA instigates r lease of inflammatory signals from 
adipocytes that subsequently activate adjacent preadipocytes. Mechanisms of 10,12 CLA-
mediated inflammatory signaling and insulin resistance involve activation of the protein 
kinases JNK and DGKs. These findings are expected to contribute critical insights for the 
development of safe and effective therapeutic strategies for weight control.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Overview 
 
  Obesity is one of the most prevalent nutrition-related diseases worldwide and in 
the U.S. Recently, it has been reported that worldwide, 1.5 billion are overweight and 500 
million are obese (1). In the U.S., 68% are overweight or obese and 34% of adults are 
obese (2).  This level of prevalence results in great conomic burden, as the total 
economic cost of overweight and obesity was ~300 billion in the U.S. and Canada in 
2009 (3). Despite efforts to reduce the prevalence of obesity, this epidemic continues to 
rise, as the percent of obese adults has risen from ~ 14% percent in 1980 to 34% percent 
in 2008 (2,4). Obesity, characterized by an expansion of white adipose tissue (WAT), is 
linked to chronic diseases such as type 2 diabetes, hypertension, and cardiovascular 
disease.  Thus, maintaining ideal body weight will decrease the incidence of obesity-
related disorders and health care costs associated with obesity.  
  One method to decrease body weight and fat mass is consumption of the 
commercially-available weight loss supplement conjugated linoleic acid (CLA). CLA, 
found naturally in ruminant meats and dairy products, refers to a group of conjugated 
octadecadienoic acid isomers that contain two double bonds separated by a single bond. 
Many isomers of CLA exist, but the two main isomers found to have biological activity 
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include the cis-9, trans-11 (9,11) isomer and the trans-10, cis-12 (10,12) isomer. 
Consuming a mixture of these isomers has been shown t  decrease adiposity in animals 
and some humans. Our lab group and others have shown that of the two major isomers, 
the 10,12 isomer is responsible for CLA’s anti-obesity properties. For example, we have 
demonstrated that 10,12 CLA, but not 9,11 CLA, decreases fatty acid and glucose uptake 
and triglyceride (TG) content of newly differentiated primary human adipocytes (5,6). 
However, 10,12 CLA increases inflammatory cytokine and prostaglandin secretion from 
adipocytes, resulting in adverse metabolic consequences such as insulin resistance 
(7,8,9). 
   Results from our lab suggest that 10,12 CLA-mediat  delipidation is linked to 
inflammatory signaling and insulin resistance. For example, we have demonstrated that 
10,12 CLA induces inflammation and insulin resistance via elevation of intracellular 
calcium levels (8), activation of extracellular signal-regulated kinase (ERK) (7), and 
nuclear factor kappa B (NFκB) (9), which upregulate inflammatory proteins such as 
tumor necrosis factor alpha (TNFα) and interleukin (IL)-6. Secretion of these cytokines 
attenuates the activation of transcription factors, such as peroxisome proliferator-
activated receptor (PPAR)γ and sterol regulated enhancer binding protein (SREBP)-1c, 
that promote glucose and fatty acid uptake, fatty acid synthesis, and TG storage in 
adipocytes. However, the cell type in our cultures of newly differentiated primary human 
adipocytes responsible for initiating inflammatory signaling is unknown. Furthermore, 
the upstream signaling mechanisms activated by 10,12 CLA that trigger intracellular 
calcium accumulation, inflammatory protein activation (i.e., ERK and NFκB), and result 
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in insulin resistance and delipidation are unknown. Elucidating the signaling pathways 
activated by 10,12 CLA will provide valuable information on the efficacy, specificity, 
and potential side effects of CLA consumption for use as a weight loss agent. Lack of 
such knowledge is an important problem, because until it becomes available, CLA’s 
potential use as a safe weight loss supplement cannot be evaluated. Therefore, the focus 
of this dissertation was to determine the cell type (i. ., preadipocyte or the adipocyte) 
responsible for 10,12 CLA-mediated inflammation and the mechanisms involved. 
 
Central Hypothesis and Specific Objectives 
  The central hypothesis for the proposed research is that adipocytes are the major 
mediators of 10,12 CLA-induced inflammation, which in turn stimulate neighboring 
preadipocytes to produce inflammatory cytokines. These inflammatory agents antagonize 
PPARγ, leading to decreased lipogenesis and increased lipolysis in adipocytes.  
   In order to test this hypothesis, two specific aims were investigated using primary 
cultures of newly differentiated human adipocytes: Aim 1)  Determine whether the 
preadipocyte or the adipocyte is responsible for 10,12 CLA–mediated inflammation, 
insulin  resistance, and delipidation, and Aim 2) Identify the mechanism by which 10,12 
CLA induces inflammation, insulin resistance, and delipidation.  
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
Background and Significance 
 
Obesity and White Adipose Tissue Inflammation 
The incidence of obesity and diabetes has risen substantially over the past thirty 
years. Since 1976, the number of obese adults in America has approximately doubled 
(10). This modern rise in obesity often results from increased energy intake and 
decreased energy expenditure, leading to the storage of excess energy as triglycerides in 
white adipose tissue (WAT). Thus, obesity is characterized by the expansion of WAT 
which acts as an endocrine organ, secreting an array of dipokines that regulate a number 
of physiological processes including immunological responses, glucose homeostasis, 
appetite regulation, angiogenesis, and growth. Not surprisingly, over-expansion and 
dysregulation of WAT results in the development of serious metabolic disorders 
including hypertension, atherosclerosis, insulin resistance and type 2 diabetes. Notably, 
80% of diabetic adults are also overweight or obese. This relationship between obesity 
and insulin resistance has been attributed to inflamm tion largely from WAT, but also 
from other tissues such as the liver and muscle.  
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One of the first reports of adipose-derived inflammation was in 1993, when 
Hotamisligil and Spiegelman reported that obese mice overexpressed tumor necrosis 
factor-α (TNF-α) in WAT (11). Based on these results, Kern et al. (12) showed that 
elevated TNFα gene and protein expression in WAT of obese humans significantly 
decreased after weight loss. Later in 1997, Uysal et al. (13) demonstrated that mice 
lacking TNFα were protected from insulin resistance, providing a link between 
inflammation in WAT and metabolic disease. Since thse findings, a multitude of 
adipokines have been identified such as leptin, interleukin (IL)-8, IL-6, IL-1β, and 
monocyte chemoattractant protein (MCP)-1, all of which have been linked to insulin 
resistance (14). Thus, WAT, through secreting inflammatory adipokines, orchestrates a 
state of chronic, low-grade inflammation leading to the development of insulin resistance 
and diabetes.   
One potential obesity treatment is conjugated linoleic acid (CLA), which has been 
shown to decrease body fat mass in animals and somehu ans. Initially identified as a 
potential anti-carcinogen, CLA has been reported to prevent obesity, diabetes, or 
atherosclerosis in different animal and cell models, depending on the doses, isomers, and 
models used. Potential mechanisms for preventing these diseases include inducing cancer 
cell apoptosis, increasing energy expenditure and delipi ating adipocytes, increasing 
insulin sensitivity, or reducing aortic lesions, resp ctively. Ironically, potential side 
effects of CLA supplementation include chronic inflammation, particularly in adipose 
tissue, insulin resistance, and lipodystrophy (7, 9, 33, 53, 71, 93, 94, 95, 98). Results from 
our lab implicate a relationship between inflammatory signaling and delipidation in 
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cultures of newly differentiated primary human adipocytes. However, the exact 
mechanisms underlying this relationship have not been fully elucidated. Additionally, the 
cell type in cultures of newly differentiated adipocytes responsible for initiating the 
inflammatory response to CLA is unknown. Furthermore, more mechanistic studies are 
needed to better understand the true potential health benefits vs. risks of consuming CLA 
isomers, and their mechanisms of action.   
 
Chemistry and synthesis of CLA 
Natural Synthesis of CLA Isomers 
  CLA isomers are produced naturally in the rumen of ruminant animals by 
fermentative bacteria Butyrovibrio fibrisolvens, which isomerize linoleic acid into CLA 
isomers (Fig. 2.1).  A second pathway of CLA synthesis in ruminants is in the mammary 
gland via delta 9-desaturation of trans-11, octadecnoic acid (15).  Thus, natural food 
sources of CLA are dairy products including milk, cheese, butter, yogurt, and ice cream 
and ruminant meats such as beef, veal, lamb, and goat meat (Table 2.1).  The cis-9, trans-
10 (9,11) isomer (i.e., rumenic acid) is the predominate CLA isomer in these products 
(~80%), whereas the trans-10, cis-12 (10,12) isomer rep esents about 10%. Although 
several other isoforms of CLA have been identified, the 9,11 and 10,12 isomers appear to 
be the most biologically active (16).  Levels of CLA isomers in ruminant meats or milk 
can be augmented by dietary manipulation, including feeding cattle on fresh pasture (17) 
or by adding oils rich in linoleic acid (e.g., safflower oil) or ingredients that alter 
biohydrogenation of linoleic acid (e.g., ionophores) to their diet (18).  
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Chemical Synthesis of CLA Isomers   
  Because of the relatively low levels of CLA isomers in naturally occurring foods 
that are high in fat content, the chemical synthesis of CLA has been developed for 
making supplements and for fortifying foods.   CLA can be synthesized from linoleic 
acid found in safflower or sunflower oils under alkaline conditions, yielding a CLA 
mixture containing approximately 40% of the 9,11 isomer and 44% of the 10,12 isomer 
(Reviewed in 19).  Commercial preparations also contain approximately 4 - 10% trans-9, 
trans-11 CLA and trans-10, trans-12 CLA, as well as tr ce amounts of other isomers. 
 
Pharmacokinetics and Efficacy of CLA 
Human and Animal Studies 
  As with other long chain unsaturated fatty acids (FA)s, CLA is absorbed primarily 
in the small intestine, packaged into chylomicrons, and distributed to extra-hepatic tissues 
having lipoprotein lipase (LPL) activity or returned to the liver via chylomicron remnants 
or other lipoproteins. The average daily intake of CLA is approximately 152 - 212 mg for 
non-vegetarian women and men, respectively (20), and human serum levels range from 
10-70 µmol/L (21, 22).   
 One major discrepancy between animal and human studie  is the dose of CLA 
administered (i.e., equal levels of 9,11 and 10,12 isomers- referred to as a CLA mixture), 
when expressed per unit body weight.  For example, most adult human studies provide 3-
6 g/day of a CLA mixture, whereas rodent studies provide 0.5-1.5% of a CLA mixture 
(w/w) in the diet.  When expressed per unit of body weight, humans receive 
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approximately 0.05 g CLA/kg body weight, whereas mice received 1.07 g CLA/kg body 
weight, which is 20 times the human dose based on body weight.  Thus, part of the 
discrepancy in results obtained from human and animl studies is likely due to this large 
difference in the dose of CLA administered.  Supplementing humans with higher, or 
animals with lower, doses of CLA would address this issue.  Other discrepancies in 
experimental designs include using CLA isomer mixtures vs. single isomers, duration of 
CLA supplementation, and the age, weight, gender, and metabolic status of the subjects 
or animals.  
 
Cell Studies 
  In vitro studies have been conducted in a variety of cells types, primarily using an 
equal mixture of 9,11 and 10,12 CLA, or each isomer individually.  Doses used in cell 
studies generally range between 1-100 µM, reflecting the concentration found in human 
subjects following supplementation. Results from these studies suggest that these isomers 
are readily taken up by the cultures.  For example, we found that 10,12 CLA is readily 
incorporated into neutral- and phospholipids fractions of the primary human adipocyte 
cultures, and reduced lipid and glucose metabolism (6). Similar to in vivo studies, 9,11 
CLA acted more like the linoleic acid controls.   
  
Anti-Obesity Actions of CLA 
  Due to the substantial rise in obesity over the past 30 years, there is a great deal of 
interest in CLA as a weight loss treatment, as it has been shown to decrease body weight 
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and body fat mass (BFM). For example, supplementation with a CLA mixture (i.e., 10,12 
+ 9,11 isomers in equal concentrations) or the 10,12 isomer alone decreases BFM in 
many animal and some human studies (Reviewed in 23 and 24). Of the two major 
isomers of CLA, the 10,12 isomer is responsible for the anti-obesity properties (5, 25, 26, 
27, 28).  
 
CLA Decreases Body Weight and BFM 
  Park et al. (29) were one of the first groups to demonstrate that CLA modulated 
body composition. Compared to controls, male and femal  mice supplemented with a 
0.5% (w/w) CLA mixture had 57 and 60% less BFM, respectively. Since these findings, 
researchers have demonstrated that CLA supplementation consistently reduces BFM in 
mice, rats, and pigs (30, 31, 32, 33). For example, di tary supplementation with 1% 
(w/w) CLA mixture for 28 days decreased body weight and peri-uteral WAT mass in 
C57BL/6J mice (33).  
  In humans, some studies show that CLA decreases BFM and increases lean body 
mass (LBM), whereas others show no such effects. For example, supplementation of 3- 4 
g/day of a CLA mixture for 24 weeks decreased BFM and increased LBM in overweight 
and obese people (34). On the other hand, supplementation of 3.76 g/day of a CLA 
mixture in yogurt for 14 weeks in healthy adults had no effect on body composition (35). 
Supplementation with 3.2 g/day of a CLA mixture decreased total BFM and trunk fat 
compared to placebo in overweight subjects, but not obese subjects (36).  These 
contradictory findings among human studies may be du  to the following differences in 
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experimental design 1) mixed vs. individual CLA isomers, 2) CLA dose and duration of 
treatment, and 3) gender, weight, age and metabolic status of the subjects.   
  These anti-obesity effects of CLA do not appear to be solely due to reductions in 
food intake in animals (37, 38, 39) or humans (40, 41). Several mechanisms by which 
CLA decreases BFM will now be examined. 
 
CLA Increases LBM 
  A recent meta-analysis of 18 human, placebo-controlled CLA studies found that 
consuming the CLA mixture increased fat-free mass (FFM) by 0.3 kg, regardless of the 
duration or dose (42). When these same 18 studies were examined for reductions in BFM, 
it was shown that CLA supplementation decreased BFM by 0.05 kg/week for up to 1 year 
(23).  The average CLA mixture dose for these studies was 3.2 g/day.  Collectively, these 
meta-analyses studies suggest that CLA supplementation of humans results in a rather 
small but rapid increase in FFM or LBM, and a much larger decrease in BFM over an 
extended period of time.  The effects of CLA on FFM or LBM in humans may vary 
depending on baseline body mass index, gender, age, and exercise status of the subjects. 
  Two proposed mechanisms by which CLA increases LBM are via increasing bone 
or muscle mass. 10,12 CLA supplementation for 10 weeks with a 0.5% (w/w) CLA 
mixture increased bone mineral density (BMD) and muscle mass in C57BL/6 female 
mice (43).  CLA supplementation has been proposed to increase BMD via increasing 
osteogenic gene expression and decreasing osteoclast a tivity (43, 44).  Furthermore, 
CLA supplementation alone or with exercise increased BMD compared to control mice 
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(45). An alternative mechanism could be that CLA decreases adipogenesis of pluripotent 
mesenchymal stem cells (MSC) in bone marrow, and instead promotes their commitment 
to become bone cells.  Indeed, 10,12 CLA has been shown to decrease the differentiation 
of MSC into adipocytes and increase calcium deposition and markers of osteoblasts (46). 
In contrast, 9,11 CLA increased adipocyte differentiation and decreased osteoblast 
differentiation. Consistent with these in vitro data, CLA mixture supplementation of rats 
treated with corticosteroids prevented reductions i LBM, BMD, and bone mineral 
content (47). Increasing LBM is directly linked to an increase in basal metabolic rate 
(BMR).  
  In addition to its effects on BMD, recent evidenc supports a role of CLA in 
increasing endurance and muscle strength. For example, aximum swimming time until 
fatigue was higher in CLA fed vs. control mice (48). Aging mice supplemented with a 
CLA mixture and 10,12 CLA had higher muscle weight compared to 9,11 CLA and corn 
oil controls (49). In addition, CLA isomers increasd levels of antioxidant enzyme 
activity, ATP, and enhanced mitochondrial potential, indicating a protective effect 
against age-associated muscle loss (49). In humans, CLA increased bench press strength 
in males supplemented with 5 g/day for 7 weeks who underwent resistance training 3 
days per week (50). Furthermore, supplementation with CLA combined with creatine 
monohydrate (C) and whey protein (P) led to greater increases in bench-press and leg-
press strength than supplementation with C+P or P alone (51). Although preliminary, 
these data suggest that CLA may enhance exercise-induced muscle strength or prevent 
sarcopenia or age-related muscle loss. 
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CLA Increases Energy Expenditure 
CLA has been proposed to reduce adiposity by elevating energy expenditure via 
increasing BMR, thermogenesis, or lipid oxidation in animals (25, 39, 52). In BALB/c 
male mice fed mixed isomers of CLA for 6 weeks, body fat was decreased by 50% and 
was accompanied by increased BMR compared to controls (39). Enhanced thermogenesis 
may be associated with increased uncoupling of mitochondria via uncoupling protein 
(UCP)s, which facilitate proton transport over the inner mitochondrial membrane thereby 
leading to dissipation of energy as heat instead of ATP synthesis. UCP1 is highly 
expressed in brown adipose tissue (BAT), and in white adipose tissue (WAT) at lower 
levels. UCP3 is expressed in muscle and a number of other tissues, whereas UCP2 is the 
form expressed at the highest level across most tissues. Supplementation with a CLA 
mixture or 10,12 CLA in rodents induced UCP2 mRNA expr ssion in WAT (26, 53). 
Recently it was demonstrated that CLA increased mRNA and protein expression of 
UCP1 in WAT (54). Similarly, CLA supplementation induced UCP gene expression and 
elevated beta oxidation in muscle and liver (55, 56, 57, 58, 59).  
 
CLA Increases Fat Oxidation 
CLA has been shown to regulate the gene expression or activity of proteins 
associated with FA oxidation in adipose tissue, muscle, and the liver. For example, CLA 
induced the expression of carnitine palmitoyl transferase 1 (CPT1) in WAT of obese 
Zucker fa/fa rats (60). Additionally, 10,12 CLA increased the expression of peroxisome 
proliferator-activated receptor (PPAR)γ coactivator-1α (PGC-1α) in WAT of mice (54). 
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Consistent with these in vivo findings, 10,12 CLA increased β-oxidation in differentiating 
3T3-L1 preadipocytes (61). Furthermore, 10,12 CLA treatment increased AMP kinase 
(AMPK) activity and increased phospho- acetylCoA carboxylase (ACC) levels in 3T3-L1 
adipocytes, suggesting an increase in FA oxidation and a decrease in FA esterification to 
triglyceride (TG) (62).  
In muscle, 10,12 CLA increased CPT1 expression in hamsters fed an atherogenic 
diet (57). Supplementation of a CLA mixture in high fat fed hamsters led to increased 
CPT1 activity in muscle (63). A CLA mixture increasd CPT1b, UCP3, acetyl CoA 
oxidase (ACO) 2, and PPARα mRNA levels in skeletal muscle of Zucker rats (64).  
Consistent with these data, 10,12 CLA increased mRNA levels (60) and activity (65) of 
CPT1 in the liver. Additionally, 10,12 CLA increased hepatic peroxisomal fatty ACO 
activity (65), suggesting increased peroxisomal beta oxidation in addition to 
mitochondrial oxidation. These findings suggest CLA may reduce adiposity through 
increased energy expenditure via increased mitochondrial uncoupling and FA oxidation 
in WAT, muscle, and liver. 
At least one report demonstrates that CLA increases FA oxidation in human 
subjects (66).  In this study, overweight adults supplemented with 4 g/day of a CLA 
mixture for 6 months had a lower respiratory quotient (RQ), indicating an increase in FA 
oxidation compared to placebo controls. However, others have shown no effect of CLA 
on energy expenditure or fat oxidation in humans (67, 68).  These discrepancies may be 
due to the length of treatment, time period of measurement, and time at which 
measurements are taken. For instance, CLA treatment for 4-8 weeks had no effect on 
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energy expenditure or FA oxidation, based on a 20 minute measurement during resting 
and walking (67). In contrast, the study by Close et al. (66) gave CLA for 6 months and 
measured FA oxidation over a 24 hour period.  Thus, discrepancies in this area may be 
due to insufficient duration of CLA treatment or measurements of energy expenditure or 
FA oxidation. 
 
CLA Decreases Adipocyte Size 
  Lipolysis is the process by which stored TG is mobilized, releasing free FAs and 
glycerol for use by metabolically-active tissues.  C57BL/6J mice fed 10,12 CLA for 3 
days had increased mRNA levels of  hormone sensitive lipase (HSL), a key enzyme for  
TG hydrolysis (53).  Consistent with these data, acute treatment with CLA mixture or 
10,12 CLA alone increased lipolysis in 3T3-L1 (29, 6 ) and newly differentiated human 
adipocytes (9).  In vitro, a CLA mixture and to a greater extent 10,12 CLA decreased TG 
content, adipocyte size, and lipid locule size in adipocytes (70). Similarly, mice fed 1% 
CLA displayed increased numbers of small adipocytes with a reduction in the number of 
large adipocytes (71). Furthermore, a CLA mixture reduced adipocyte size rather than 
cell number in Sprague Dawley (37) and fa/fa Zucker rats (72). Thus, CLA may reduce 
adipocyte size by increasing lipolysis. 
 
CLA Decreases Adipocyte Number  
  Apoptosis is another mechanism by which CLA may reduce BFM.  Apoptosis can 
occur through activation of the death receptor pathw y, endoplasmic reticulum (ER) 
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stress, or the mitochondrial pathway. A number of in vivo and in vitro studies have 
reported apoptosis in adipocytes supplemented with a CLA mixture or 10,12 CLA alone 
(53, 61, 73, 74).  For example, supplementation of C57BL/6J mice with 1% (w/w) CLA 
mixture reduced BFM and increased apoptosis in WAT (71). Mice fed a high-fat diet 
containing 1.5% (w/w) CLA mixture had an increased ratio of BAX, an inducer of 
apoptosis relative to Bcl2, a suppressor of apoptosis (75). Reported mechanisms by which 
CLA reduces adiposity are shown in Fig. 2.2. 
 
CLA Decreases Adipocyte Differentiation 
  The conversion of preadipocytes to adipocytes involves the activation of key 
transcription factors such as PPARγ and CAAT/ enhancer binding proteins (C/EBPs). 
There is much evidence showing that CLA suppresses pr adipocyte differentiation in 
animal (76, 77, 78) and human (6, 7) preadipocytes treated with a CLA mixture or 10,12 
CLA alone. 10,12 CLA treatment has been reported to decrease the expression of PPARγ, 
C/EBPβ, sterol regulatory element binding protein 1c (SREBP-1c), liver X receptor 
(LXRα), and adipocyte fatty acid binding protein (aP2), thereby reducing adipogenesis 
and lipogenesis (6, 26, 78).  
  In rodents, supplementation of 10,12 CLA decreased th  expression of PPARγ 
and its target genes (47, 78, 79). In contrast, humans supplemented with a CLA mixture 
had higher mRNA levels of PPARγ in WAT, but no difference in body weight or BFM 
(35). In mature, in vitro-differentiated primary human adipocytes or in mature 3T3-L1 
adipocytes, 10,12 CLA treatment leads to a substantial decrease in the expression and 
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activity of PPARγ (80, 81), and a decrease in PPARγ target genes and lipid content (7). 
This shows that 10,12 is not only able to inhibit, ut also to reverse the adipogenic 
process and indicates that this may be mediated by suppression of PPARγ activity.  In 
addition to its effect on PPARγ, 10,12 CLA may also directly impact the activity of other 
transcription factors involved in adipogenesis and lipogenesis (i.e., LXRα, C/EBPs, 
SREBP-1c), which could contribute to CLA’s anti-obesity actions.   
 
CLA Decreases Glucose and FA Uptake and TG Synthesis  
  Conversion of glucose and FAs to TG is a major function of adipocytes.  Genes 
involved in lipogenesis, such as a lipoprotein lipase (LPL), ACC, fatty acid synthase 
(FAS), and stearoyl-CoA desaturase (SCD), were decreased following supplementation 
with mixed isomers of CLA or 10,12 CLA alone (6, 53, 69, 7). PPARγ is a major 
activator of many lipogenic genes including glycerol-3-phosphate dehydrogenase 
(GPDH), LPL, and lipin as well as many genes encoding lipid droplet associated proteins 
such as perilipin, adipocyte differentiation-related protein (ADRP), and cell death-
inducing DFFA-like effector c (CIDEC) (82). Thus, the anti-lipogenic action of 10,12 
CLA may be explained by inhibition of PPARγ activity. In addition, CLA repression of 
expression of SREBP-1 and its target genes may play an important role in delipidation. 
Finally, CLA suppression of insulin signaling may also impair insulin’s ability to activate 
or increase the abundance of a number of lipogenic proteins including LPL, ACC, FAS, 
SCD-1, and the insulin-dependent glucose transporter (GLUT4).   
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CLA Increases Markers of Inflammation  
  Adverse side effects have been reported for CLA supplementation such as 
elevated levels of inflammatory markers, lipodystrophy, steatosis, and insulin resistance. 
Most adverse side effects are due to the 10,12 CLA isomer. Treatment with 10,12 CLA 
increases the expression or secretion of inflammatory markers such as TNFα, interleukin 
(IL)-1β, IL-6, and IL-8 from adipocyte cultures (53, 9, 7, 79, 81). Secretion of these 
inflammatory factors further exacerbates inflammatory signaling in WAT via paracrine 
and autocrine signaling (7). For example, TNFα stimulates lipolysis, inhibits lipogenesis, 
and thus promotes delipidation in adipoyctes (83, 84). Our lab has linked 10,12 CLA-
mediated inflammation to an increase in intracellular calcium accumulation (85), and 
MEK/ERK and NFκB activation (7, 9). Activated NFκB can transrepress PPARγ via 
direct binding to PPARγ or its co-activators, thereby preventing binding of PPARγ to 
target genes (86, reviewed in 87). Moreover, CLA increases the phosphorylation of 
phospholipase (PLA)2 (85) and the expression of cyclooxygenase (COX)-2, an enzyme 
involved in the synthesis of PGs, and the secretion of PGF2α (78, 88). These inflammatory 
pathways are known to antagonize PPARγ activity and insulin sensitivity (75, 88, 89, 90).  
 Consistent with these in vitro data, 10,12 CLA supplementation increases the levels 
of inflammatory cytokines and PGs in humans (91, 92).  For example, women 
supplemented with 5.5 g/day of a CLA mixture for 16 weeks had higher levels of C-
reactive protein in serum and 8-iso-PGF2α in urine (41). 10,12 CLA supplementation in 
mice resulted in macrophage recruitment in WAT (79).  In contrast, 9,11 CLA appears to 
have anti-inflammatory actions (17).  
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CLA Causes Insulin Resistance   
Insulin resistance has been reported in vivo (53, 93, 94, 95) and in vitro (6, 9, 78, 88) 
following supplementation with a CLA mixture or 10,2 CLA alone. For example, 10,12 
CLA supplementation of 3.4 g/day for 12 weeks in obese men with metabolic syndrome 
increased serum glucose and insulin levels and decreased insulin sensitivity (93). 
Supplementation with a CLA mixture in type 2 diabetics increased fasting plasma 
glucose levels and reduced insulin sensitivity (94). Mice fed 1% (w/w) 10,12 CLA 
displayed elevated fasted and feeding plasma insulin levels and had reduced insulin 
sensitivity (71). Consistent with these data, the mRNA levels of adiponectin, a key 
adipokine associated with insulin sensitivity, decreases following supplementation with 
10,12 CLA in vivo (33, 79, 90) and in vitro (78, 80, 96, 97). Additionally, our lab group 
has shown that 10,12 CLA decreases fatty acid uptake and insulin-stimulated glucose 
uptake in primary cultures of newly differentiated human adipocytes (7). The reduction 
of fatty acid and glucose uptake is likely due to decreases in PPARγ activity and protein 
levels, and thus the suppression of genes involved in glucose and fatty acid uptake and 
storage, such as aP2, and GLUT4.  
 
CLA Causes Lipodystrophy  
The combination of inflammation and insulin resistance results in reduced FA and 
glucose uptake in WAT, leading to lipid accumulation in the blood (hyperlipidemia), 
liver (steatosis), or muscle. CLA-mediated hyperlipidemia and steatosis has been reported 
in several animal studies (33, 71, 98). For example, 1% (w/w) CLA time-dependently 
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increased insulin levels and led to increased liver w ight and liver lipid accumulation in 
C57BL/6J mice (33). Aging C57BL/6J mice fed 0.5% 10,12 CLA displayed increased 
insulin resistance and liver hypertrophy (98).  
 
Cell Types Responsible for CLA-Mediated Inflammation in WAT 
The primary cell types in adipose tissue responsible for mediating inflammation 
and insulin resistance are under debate. Adult human WAT has been reported to contain 
~ 50-70% adipocytes, ~ 20-40% preadipocytes, and ~ 1-30% infiltrated macrophages (14, 
99). These percentages also depend on body composition. For example, Tchoukalova et 
al. (100) found that WAT of lean women contain approximately 30% preadipocytes, 
whereas WAT of obese women contain only 17% preadipocytes. However, the 
localization and secretory pattern of cytokines in WAT are unknown. Some researchers 
suggest that non-fat cells are the key players in cytokine release from adipose tissue (101, 
102). Fain et al. (101) has shown that non-fat cells are responsible for up to 90% of 
adipokine release from adipose tissue compared to mature adipocytes. These samples, 
obtained from obese women directly after undergoing bariatric surgery, were analyzed 
for basal levels of inflammatory markers. Our lab group has shown that 
lipopolysaccharide (LPS)-stimulated preadipocytes display a greater extent of 
inflammatory signaling than adipocytes (103). On the other hand, LaRosa et al. (53) 
showed that 10,12 CLA-induced inflammatory genes were higher in murine adipocytes 
compared to preadipocytes. In addition, Ajuwon et al. (104) demonstrated that a saturated 
fatty acid, palmitate, induces IL-6 and TNFα expression in 3T3-L1 mature adipocytes. 
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Skurk et al. (105) proposes that adipocyte size is an important determinant of adipokine 
secretion, where proinflammatory cytokine secretion ( .e., IL-6, IL-8, MCP-1, and TNFα) 
was significantly higher from large adipocytes compared to smaller adipocytes. 
Interestingly, Suganami et al. (106, 107) reported that activated hypertrophied adipocytes 
release saturated free fatty acids (FFA) that subsequently promote TNFα secretion from 
macrophages, leading to an inflammatory cycle in adipose tissue. Taken together, these 
conflicting results suggest that differences in the inflammatory capacity of preadipocytes 
vs. adipocytes, may be due to 1) inflammatory stimuli, 2) adipocyte size, and 3) crosstalk 
with other cell types.   
 
Conclusions 
There is an abundance of evidence in animals suggestin  that CLA consumption may 
reduce the incidence or risk of developing obesity depending on the type and abundance 
of CLA isomer consumed and the physiological status of the animal model.  Data on the 
anti-obesity properties of 10,12 CLA in animals, especially mice, are the most 
reproducible.  However, these potential benefits are not without risks, as the 10,12 isomer 
is associated with increased levels of inflammatory markers, lypodystrophy, and insulin 
resistance.  More clinical studies are needed to determine the efficacy of CLA isomers in 
humans, and more mechanistic animal and cell studies ar  needed to determine the 
precise, isomer-specific mechanisms of action of CLA, potential side effects, and the cell 
types responsible for these adverse effects. 
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 Chapter III will address the hypothesis that 10,12 CLA initiates inflammatory 
signaling from adipocytes vs. preadipocytes. Chapter IV will address the hypothesis that 
10,12 CLA mediates inflammatory signaling via activa on of the MAPK, JNK, using the 
chemical JNK inhibitor SP00125. Chapter V will address the hypothesis that 
diacylglycerol kinases play a role in 10,12 CLA-mediated inflammation, insulin 
resistance, and delipidation using the DGK inhibitor R59022.   
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Table 2.1  CLA content of various foods. 
 
Sources: Based on values reported in Lin, H. et al. J. Dairy Sci 1995, 78 (11), 2358-2365; 
Chin, S. et al. J. Food Comp. Anal. 1992, 5, 185-197; Fritsche, J.;  Steinhardt, H. Food 
Res. Tech. 1998, 206, 77-82; and the University of Wisconsin Food Research Institute 
(Dr. Pariza, Director) 
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Figure 2.1  Stuctures of linoleic acid, cis-9, trans11 CLA, and trans-10, cis-12 CLA. 
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Figure 2.2 Reported mechanisms by which 10,12 CLA decreases adipose tissue mass and 
obesity.  
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CHAPTER III 
 
 TRANS-10, CIS-12 CONJUGATED LINOLEIC ACID INSTIGATES 
INFLAMMATION IN HUMAN ADIPOCYTES COMPARED TO PREADIPOCYTES  
 
 
Abstract 
 We previously showed in primary human (pre)adipocytes that lipopolysaccharide 
(LPS) and trans-10, cis-12 (10,12) conjugated linoleic acid (CLA) activate inflammatory 
signaling that promotes insulin resistance. Because o r published data demonstrated that 
preadipocytes were the primary instigators of inflammatory signaling in LPS-treated 
cultures, we hypothesized that they played the same rol  in 10,12 CLA-mediated 
inflammation. To test this hypothesis, we employed four distinct models. In Model 1, a 
Differentiation Model, CLA activation of mitogen activated protein kinases (MAPK) and 
induction of interleukin (IL)-8, IL-6, IL-1β, and cyclo-oxygenase (COX)-2 were greatest 
in differentiated compared to undifferentiated cultures. In Model 2, a Cell Separation 
Model, the mRNA levels of these inflammatory proteins were increased by 10,12 CLA 
compared to BSA vehicle in the adipocyte fraction (ADF) and the preadipocyte fraction 
(PDF). In Model 3, a Co-Culture Insert Model, insert  containing ~50% adipocytes 
(AD50) or ~100% preadipocytes (AD0) were suspended over wells containing AD50 or 
AD0 cultures. 10,12 CLA-induced IL-8, IL-6, IL-1β, and COX-2 mRNA levels were 
highest in AD50 cultures when co-cultured with AD0 inserts. In Model 4, a Conditioned 
Media (CM) Model, CM collected from CLA-treated AD50, but not AD0 cultures, 
induced IL-8 and IL-6 mRNA levels and activated phosphorylation of MAPK in naïve 
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AD0 and AD50 cultures. Consistent with these data, 10,12 CLA-mediated secretions of 
IL-8 and IL-6 from AD50 cultures were higher than from AD0 cultures. Notably, 
blocking adipocytokine secretion prevented the inflammatory capacity of CM from 10,12 
CLA-treated cultures.  These data suggest that CLA instigates release of inflammatory 
signals from adipocytes that subsequently activate adjacent preadipocytes. 
 
Introduction 
 Obesity is the most prevalent nutrition-related disease in the U.S., where 66% of the 
adult population is classified as overweight or obese (1). Obesity is linked to chronic 
diseases, such as type 2 diabetes, hypertension, and cardiovascular disease.  Annual 
health care costs for treating the overweight and obese population are ~ $100 billion. 
Thus, maintaining ideal body weight will decrease th incidence of and health care costs 
associated with obesity.  However, current strategies that promote effective and safe 
weight loss or maintenance are lacking. 
 Notably, a commercially-available weight loss supplement containing two equal 
levels of conjugated linoleic acid (CLA) isomers [i.e., cis-9, trans-11 (9,11) and trans-10, 
cis-12 (10,12)] decreases adiposity or increases lean body mass in animals (2-6) and 
some humans (7-10).  It appears that 10,12 CLA, rathe  han 9,11 CLA, is the anti-
obesity isomer in this supplement (reviewed in 11).  Potential mechanisms responsible 
for these anti-obesity properties of 10,12 CLA include 1) decreasing energy intake or 
increasing energy expenditure (12-16), 2) decreasing lipogenesis or increasing lipolysis 
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(17-20), 3) decreasing adipogenesis or increasing delipi ation (21-25), or 4) increasing 
adipocyte apoptosis (26-28).   
 There is, however, concern about potential adverse side effects of CLA 
supplementation, including lipodystrophy (28), steatosis (29), macrophage infiltration to 
white adipose tissue (WAT; 5), and insulin resistance (9, 30-32).   For example, the 10,12 
isomer of CLA caused increased insulin resistance (33) and increased markers of 
oxidative stress [e.g., iso-prostaglandin (PG) F2α] and atherosclerosis [e.g., C-reactive 
protein (CRP); 34] in obese men with Metabolic Syndrome. Consistent with these data, 
CLA supplementation (i.e., equal levels of 9,11 and 10,12 isomers) adversely affected 
insulin and glucose metabolism in patients with type 2 diabetes (35). More recently, it 
was reported that supplementing postmenopausal women with an equal mixture of 10,12 
and 9,11 CLA increased serum triglyceride (TG) leves, CRP, and plasminogen activator 
inhibitor (PAI)-1, and urinary levels of iso-PGF2α compared to the 9,11 isomer alone 
(32).  Furthermore, insulin and tumor necrosis factor (TNF)α levels were elevated in the 
serum and WAT, respectively, in women consuming the CLA mixture compared to the 
olive oil controls (9).   
 Similarly, we have demonstrated that 10,12 CLA, but not 9,11 CLA, decreased the 
TG content of primary cultures of newly differentiated human adipocytes (18, 19, 23, 
25).  However, 10,12 CLA increased the expression levels of genes and proteins linked to 
chronic inflammation in these cultures, resulting i adverse metabolic consequences, such 
as insulin resistance (23, 25, 36, 37).  Indeed, chronic inflammation driven by nuclear 
factor kappa B (NF-κB) and specific mitogen activated protein kinases (MAPK) 
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antagonize peroxisome proliferator activated receptor (PPAR)γ activity, thereby 
suppressing the transcriptional activation of genes eded for glucose and fatty acid 
uptake and conversion to lipids. Consistent with these data, we have demonstrated that 
10,12 CLA-mediated suppression of PPARγ activity and target gene expression is linked 
to the activation of extracellular signal-related kinase (ERK)1/2 (23, 37) and NF-κB  
(36). Therefore, 1) the effective and safe use of CLA for weight loss or maintenance 
remains unclear, 2) the precise mechanism by which 10,12 CLA promotes inflammation 
and delipidation is unknown, and 3) the cell type in our primary cultures of human 
adipocytes responsible for mediating the inflammatory effects of CLA is unknown.  To 
better understand the connection between inflammation and delipidation induced by CLA 
in our cultures, it is important to first identify the cell type in our cultures that is 
responsible for initiating the inflammatory effects of CLA. Thus, the objective of this 
research was to identify the role that preadipocytes vs. adipocytes play in mediating 
10,12 CLA-mediated inflammation in primary cultures of newly differentiated human 
adipocytes.  
 
Experimental Procedures 
Materials and Models   
 Materials- All cell culture-ware and Hyclone fetal bovine serum (FBS) were 
purchased from Fisher Scientific (Norcross, GA). Adipocyte media (AM-1) was 
purchased from Zen-Bio. Isomers of CLA (+98% pure) were purchased from Matreya 
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(Pleasant Gap, PA). Lightning Chemiluminescence Substrate was purchased from Perkin 
Elmer Life Science (Boston, MA). Immunoblotting buffers and precast gels were 
purchased from Invitrogen (Carlsbad, CA). Primary antibodies for rabbit polyclonal 
phospho-p44/42 (Thr202/Tyr204, Cat # 9101), p44/p42 (Cat # 9102), phospho-
SAPK/JNK (c-Jun-NH2-terminal kinase; Thr183/Tyr185, Cat # 9251), SAPK/JNK (Cat # 
9252), phospho-c-Jun (Ser63 Cat # 9261S), phospho-STAT3 (Tyr705, 3E2, Cat # 9138), 
STAT3 (Cat # 9139), c-Jun (60AB, Cat # 9165), and p38 (Cat # 9217) were purchased 
from Cell Signaling Technologies (Beverly, MA). Mouse monoclonal phospho-p38 
(pT180/pY182, Cat # 612280) was purchased from BD Transduction Laboratories (San 
Jose, CA). The primary antibodies for activating transcription factor (ATF) 3 (C-19, Cat 
# sc-188) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc20357) were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Gene expression assays for 
IL-1β, interleukin (IL)-8, IL-6, cyclooxygenase (COX)-2, adiponectin (apm1), adipocyte-
specific fatty acid binding protein (aP2), adipocyte enhancer binding protein (AEBP)-1, 
and monocyte chemoattractant protein (MCP)-1 were purchased from Applied 
Biosystems Inc. (Foster City, CA). PicoGreen reagent was purchased from Molecular 
Probes (Eugene, OR). BioPlex singleplex assays for IL-6 and IL-1β were purchased from 
Bio-Rad (Hercules, CA). Recombinant human IL-6 was purchased from Fitzgerald 
Industries International (Concord, MA). Monoclonal anti-human IL-6 antibody (ab) was 
purchased from R&D Systems (Minneapolis, MN). Prostaglandin F2α (PGF2α) and AL-
8810 were purchased from Cayman Chemical (Ann Arbor, MI). All other chemicals and 
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reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise 
stated. 
 Cell Culture Models-  Abdominal WAT was obtained from non-diabetic Caucasian 
and African American females with a body mass index ≤ 32.0 and between the ages of 20 
and 50 years old who had undergone elective surgery as previously described (23). These 
selection criteria allow for reduced variation in gender, age, and obesity status. 
Institutional Review Board approval was granted through the University of North 
Carolina at Greensboro and the Moses H. Cone Memorial Hospital. Stromal vascular 
(SV) cells from human WAT were isolated via collagenase digestion and subsequently 
grown as previously described (23). CLA was administered at a physiological level of 50 
µM. Each experiment was repeated at least twice using a mixture of cells from at least 
three different subjects unless otherwise indicated. 
 Because our previous CLA studies had been conducte in primary cultures of human 
adipocytes containing ~50% preadipocytes and 50% adipocytes (see 36 for marker 
analyses of these cells), we did not know which cells were instigating inflammation or 
insulin resistance in response to CLA treatment.  To better understand the extent to which 
preadipocytes and adipocytes initiated inflammation in these cultures, we developed four 
distinct cell models described below. 
 Model 1- Differentiation Model. Four human (pre)adipocyte cell models containing ~ 
0, 10, 30, and 50% adipocytes (i.e., AD0, AD10, AD30, and AD50) were established by 
modulating exposure to differentiation media (DM-1) containing 250 µM 
isobuthylmethylxanthine (IBMX) and 1 µM Rosiglitazone (BRL, a PPARγ agonist 
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generously provided by Dr. Per Sauerberg at Novo Nordisk A/S, Copenhagen, Denmark).  
SV cells were seeded into 35 mm dishes at 4 x 104 cells/cm2. AD0 cultures received no 
DM-1 for 8 d (NT). AD10, AD30, and AD50 cultures were supplemented with DM-1 for 
5 h, 3 d, or 6 d, respectively (Fig. 3.1A). Cells were treated with 50 µM 10,12 CLA for 
12 h and harvested on d 8. For MAPK and AP-1 activation shown in Fig. 3.3, cells were 
treated for 6, 12, and 24 h.   
 Model 2- Cell Separation Model. SV cells were grown in 100 mm dishes containing ~ 
3 million cells and were differentiated to ~ 30% adipocytes (AD30). On day 8, cells were 
treated with 50 µM 10,12 CLA or BSA vehicle for 12 h (Fig. 3.4). Cells were washed 
with Hanks Balanced Salt Solution (HBSS) containing 0.5 mM EDTA and trypsinized 
with trypsin-like enzyme at 37ºC for 10 min. Cells were layered on 6% iodixanol 
(Optiprep;Axis-Shield, Oslo, Norway; ~1.03 g/ml) in HBSS containing 0.5% BSA in a 
15 ml centrifuge tube and centrifuged at 650 x g for 20 min at 4ºC. The floating 
adipocytes were collected from the top of the tube and placed in a 1.5 ml microcentrifuge 
tube and resuspended in HBSS and recentrifuged for 5 min at 5000 x g to remove any 
cell debris. The remaining supernatant was removed and the SV cells were collected from 
the pellet and transferred to a microcentrifuge tube. TriReagent was added to each tube 
for RNA extraction. 
 Model 3- Co-Culture Insert Model. SV cells were seeded in cell culture inserts seeded 
with 0.2 million cells per insert or in 6-well Multiwell™ plates seeded at 4 x 104 
cells/cm2. Inserts and wells received either AM-1 until d 8 to achieve AD0 cultures or 
DM-1 for 6 d to achieve AD50 cultures. At d 8 of diferentiation, inserts were transferred 
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over underlying wells and a recovery period of ~15 h was allotted to allow for a decrease 
in potential stress due to the transfer (Fig. 3.5). Next, both wells and inserts were 
supplemented with 50 µM 10,12 CLA or BSA vehicle control for 12 h and inflammatory 
gene expression was measured via qPCR in cultures ha vested from the underlying wells. 
 Model 4- Conditioned Media (CM) Model. SV cells were seeded in 60 mm dishes at 4 
x 104 cells/cm2. Cultures received either AM-1 for 8 d or DM-1 for 6 d to achieve AD0 
and AD50 cultures, respectively (Fig. 3.6). On d 8, cells were treated with 50 µM 10,12 
CLA or BSA control for 24 h after which CM was collected and stored at -80°C for 
subsequent experiments. Naïve AD0 and AD50 cultures were treated with a 1:1 ratio of 
thawed CM and fresh AM-1 at d 8 of differentiation.  
 
Methods 
 Lipid and Nuclear Staining and TG Content- Intracellular lipid and nuclei were 
visualized by staining cultures with ORO and Mayer’s Hematoxylin, respectively, as 
previously described (18). For establishing the Differentiation Model, photomicrographs 
were taken using an Olympus Microscope Digital Camer  Model DP71 to provide 
micrographs of the degree of lipid accumulation in relation to nuclei in the cultures. In 
Fig. 3.1B, three fields were captured per well with three replicates per treatment group 
(i.e., AD0, AD10, AD30, and AD50). Therefore, a total of nine pictures were taken per 
treatment group. Data were expressed as the percentage of ORO-stained adipocytes to 
total cell number.  TG levels were determined with a modified commercially-available 
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TG assay as previously described (19). To normalize the TG content, DNA was isolated 
using a DNeasy® Blood & Tissue Kit (QIAGEN, Valencia, CA) and then quantified 
using Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen; Molecular Probes, 
Carlsbad, CA).  
 RNA Isolation and qPCR- RNA was isolated from cell cultures using TriReagent 
(Molecular Research Center; Cincinnati, OH) following the manufacturer’s protocol for 
RT-PCR. For real-time quantitative (q) PCR, 2 µg total RNA was used to generate first-
strand cDNA using Applied Biosystems High Capacity DNA Archive Kit (Foster City, 
CA). qPCR was performed using a 7500 Fast Real-Time PCR system (Applied 
Biosystems) using TaqMan® Universal PCR Master Mix and Taqman Gene Expression 
Assays. To account for possible variation related to cDNA input amounts or the presence 
of PCR inhibitors, the endogenous reference gene GAPDH was simultaneously 
quantified for each sample in separate wells of the same 96-well plate. 
 Immunobloting-  Immunoblotting was conducted as previously described using 
NuPage precast gels from Invitrogen (23). 
 Secretion of IL-6 and IL-8 via Multiplex Cytokine Assay- The concentrations of IL-6 
and IL-8 were determined using the BioPlex® Suspension Array System from Bio-Rad 
(Hercules, CA) following the manufacturer’s protocol.   
 Quantification of PGE2 and PGF2- PGE2 and PGF2 were measured with a stable 
isotope dilution gas chromatographic/negative ion chemical ionization-mass 
spectrometric (GC/NICI/MS) assay (38).  Briefly, PGE2-d4 (2.12 ng) and PGF2-d4 (0.84 
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ng) internal standards were added to the media samples. The sample was then acidified to 
pH 3.0 with 1 N HCl and extracted on a C18 Sep-Pak. GE2 and PGF2 were eluted with 
ethyl acetate:heptane and evaporated under a stream of nitrogen (N2). PGE2 and PGF2 in 
methoxylamine solution were extracted with ethyl acet te and evaporated with N2. The 
pentafluorobenzyl esters were purified by thin layer chromatography (TLC; PGF2 and PGE2 
methyl esters were used as TLC standards), converted to O-methyloxime pentafluorobenzyl 
ester trimethylsilyl derivatives, and PGE2 and PGF2 were dissolved in undecane that was 
dried over a bed of calcium hydride. GC/NICI/MS analysis was performed as described 
previously with the ions for PGE2 (m/z 526) and the [
4H2]-PGE2 as internal standard (m/z 
528) and the ions for PGF2 (m/z 569) and the [
4H2]-PGF2 as internal standard (m/z 573). 
 Quantification of Isoprostanes (IsoP)s- Total F2-IsoPs were measured by GC/MS 
with selective ion monitoring (39, 40). Briefly, cells were resuspended in 0.5 ml of 
methanol containing 0.005% butylated hydroxytoluene, sonicated, and then subjected to 
chemical saponification with 15% KOH to hydrolyze bound F2-IsoPs. The cell lysates 
were adjusted to a pH of 3.0, followed by the addition of 0.1 ng of 4H2-labeled 15-F2-
IsoP internal standard. F2-IsoPs were subsequently purified by C18 and silica Sep-Pak 
extraction and by TLC. They were subsequently analyzed with pentafluorobenzyl ester, a 
trimethylsilyl ether derivative, via GC/NICI/MS assay. 
 Lipolysis Assay- [14C]-oleic acid release into CM was measured after 3, 9, or 24 h 
treatment of (pre)adipocyte cultures with 10,12 CLA or BSA vehicle as previously 
described (20).  
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 Statistical Analysis-  Statistical analyses were performed for data in Figs. 3.1B- C, 
and 9B using one-way ANOVA. Analyses were performed for data in Figs. 3.2, 3.4B-C, 
3.5B, 3.6B, 3.7, 3.8A, and 3.9A using two-way ANOVA with interaction (JMP version 
6.03, SAS Institute). Data in Figs. 3.8B were analyzed by a multifactor ANOVA with 
interaction. Student’s t tests were used to compute individual pairwise comparisons of 
least square means (P < 0.05). Data are expressed a the means ± SE.  Number of 
replicates and independent experiments varies with eac  outcome. 
 
Results 
Differentiation Model 
 Cell Types in Our Cultures-  We previously identified the predominate type of cells in 
our primary cultures of newly differentiated human adipocytes based on marker analysis 
(41). Undifferentiated cultures lacking DM-1 supplem ntation consisted of preadipocytes 
(i.e., + for Pref-1 and - for aP2 and PPARγ).   Differentiated cultures supplemented with 
DM-1 media consisted of preadipocytes and adipocytes (i. ., + for Pref-1 or aP2 and 
PPARγ, respectively). None of the cells were positive for markers of myocytes (e.g., 
MyoD) or macrophages (e.g., CD-68, MAC-1). Based on these findings, undifferentiated 
cells (i.e., lacking aP2 or PPARγ expression, TG content, or visible lipid droplets) 
discussed in this article will be referred to as preadipocytes.  
 The Percentage of Lipid-filled Adipocytes Increases as the Duration of Rosiglitazone 
(BRL) Treatment Increases-  We previously demonstrated in primary cultures of newly 
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differentiated human adipocytes that 10,12 CLA promotes inflammatory signaling, 
insulin resistance, and delipidation (23, 25, 36,  37). We have also shown that 
preadipocytes are the primary instigators of inflammation and insulin resistance induced 
by lipopolysaccharide (LPS) in our cultures (41). Based on these data, we originally 
hypothesized that preadipocytes would be the instigators of the inflammatory response to 
10,12 CLA. In order to determine whether the preadipocytes or the adipocytes were 
responsible for 10,12 CLA-mediated inflammatory signaling, we developed a 
Differentiation Model in which various levels of differentiation were achieved as 
described in the Materials and Models section. As shown in Fig. 3.1A, the percentage of 
adipocytes stained with ORO relative to total cell number increased as the duration of 1 
µM BRL treatment increased from no treatment (NT) to 6 d of treatment. BRL untreated 
cultures showed no ORO-stained adipocytes, whereas cultures that received 1 µM BRL 
for 5 h, 3 d, or 6 d yielded ~ 10, 30, or 50% ORO-stained adipocytes, respectively (Fig. 
3.1B). Furthermore, TG content in AD30 and AD50 cultures was significantly greater 
than in AD0 or AD10 cultures (Fig. 3.1C). Therefore, by manipulating the duration of 
treatment with the PPARγ agonist BRL, a Differentiation Model was established that had 
four distinct levels of lipid-filled adipocytes in the cultures.  
 Adipocytes Play an Essential Role in 10,12 CLA-induce  Inflammatory Gene 
Expression and Activation of MAPK  and Activating Protein (AP)-1 Subunits-  Gene 
expression of preadipocyte (i.e., AEBP-1) and adipocyte [aP2 and adiponectin (apm1)] 
markers were analyzed to verify levels of preadipocytes and adipocytes in each group of 
the Differentiation Model (Fig. 3.2A). The expression AEBP-1 was highest in the AD0 
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cultures and decreased as the level of differentiation increased. In contrast, the mRNA 
levels of aP2 and apm1 were lowest in the AD0 cultures, and increased as the level of 
differentiation increased. Consistent with previous findings (23), 10,12 CLA attenuated 
aP2 and apm1 gene expression compared to BSA control in AD30 and AD50 cultures. 
 To determine which experimental group (i.e., AD0, AD10, AD30, or AD50) 
displayed the greatest level of inflammatory signaling in response to 10,12 CLA 
treatment, gene expression of inflammatory cytokines and COX-2 were analyzed. 
Cultures were treated with 50 µM 10,12 CLA, 9,11 CLA, or BSA vehicle for 12 h. These 
dose and time points were selected based on previous t me course and dose response 
studies conducted in our lab (25, 37). In contrast to previous findings with LPS as an 
inflammatory stimulant, 10,12 CLA treatment caused the greatest increase in the 
expression of IL-8, IL-6, IL-1β, and COX-2 in AD50 cultures compared to all other 
groups (Fig. 3.2B). The induction of these genes by 10,12 CLA was greater in AD50 
compared to AD30 cultures. Furthermore, 10,12 CLA did not induce inflammatory genes 
in AD0 or AD10 cultures compared to BSA. Consistent with our previous findings (19, 
23, 37), the inflammatory effect of CLA was specific to the 10,12 isomer, where 9,11 
CLA did not induce inflammatory gene expression compared to BSA vehicle. 
 Given the role of MAPK and AP-1 in activating inflammatory gene expression during 
cellular stress, their activation by 10,12 CLA in AD50 vs. AD0 cultures was examined. 
10,12 CLA robustly increased the phosphorylation of ERK, JNK, and p38 at 12 and 24 h 
in AD50 vs. AD0 cultures compared to BSA controls (Fig. 3.3A). Similarly, 10,12 CLA 
increased the levels of ATF3 and P-c-Jun at 12 and 24 h in the AD50 cultures, but not in 
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the AD0 cultures, compared to BSA controls (Fig. 3.3B). Collectively, these data suggest 
that adipocytes are essential for 10,12 CLA-mediate activation of MAPK and 
transcription factors and induction of genes associated with inflammation.    
 
Cell Separation Model 
 10,12 CLA Induces Inflammatory Gene Expression in Adipocytes and Preadipocytes 
from Mixed Cultures- The Cell Separation Model, as described in the Methods section 
and shown in Fig. 3.4A, was used to demonstrate that adipocytes are responsible for the 
inflammatory response induced by 10,12 CLA in mixed cultures of preadipocytes and 
adipocytes. On d 8, cells were treated with 50 µM 10,12 CLA or BSA vehicle for 12 h 
and fractionated to yield a floating ADF and a pellet d PDF. The preadipocyte marker 
AEBP-1 was expressed at higher levels in the PDF compared to the ADF (Fig. 3.4B). 
Adipocyte-specific genes, aP2 and apm1, were expressed at higher levels in the ADF 
compared to the PDF (Fig. 3.4B). As expected, 10,12 CLA decreased aP2 and apm1 gene 
expression in the ADF. 
 Surprisingly, the expression of IL-8, IL-6, and COX-2 induced by 10,12 CLA was 
greater than BSA vehicle controls in the PDF and the ADF (Fig. 3.4C). Thus, we 
hypothesized that the inflammatory response to 10,12 CLA in the PDF may be due to 
cross-talk between adipocytes and preadipocytes prior to fractionation, as there is cell-to-
cell contact in these mixed cultures (AD30) during the 12 h treatment with 10,12 CLA. 
Alternatively, it is possible that immature adipocytes contaminated the PDF. However, 
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adipogenic gene expression was much greater in the ADF compared to the PDF, so the 
possibility that a significant number of adipocytes contaminated the PDF is unlikely. 
Thus, a third model was utilized to better understand 10,12 CLA-induced inflammatory 
gene expression and potential cross-talk between adipocytes and preadipocytes. 
 
Co-Culture Insert Model  
 Preadipocytes Enhance the Inflammatory Response to 10,12 CLA in Adipocytes-  To 
determine the extent to which adipocytes communicate wi h preadipocytes during 10,12 
CLA treatment, AD0 and AD50 cultures were grown in inserts and suspended over 
underlying wells containing AD0 or AD50 cultures during treatment with 50 µM 10,12 
CLA or BSA vehicle for 12 h (Fig. 3.5A). Gene expression was measured only in cells 
grown in underlying wells.  
 Consistent with the Differentiation Model, 10,12 CLA did not induce inflammatory 
gene expression in preadipocytes (AD0), regardless of whether preadipocyte (AD0 + 
AD0 insert) or adipocyte (AD0 + AD50 insert) inserts were suspended above them (Fig 
3.5B). Also consistent with the Differentiation Model, 10,12 CLA-induced inflammatory 
gene expression was greater in AD50 vs. AD0 cultures. However, the mRNA levels of 
genes induced by 10,12 CLA were greatest in AD50 cultures when AD0-containing 
inserts were suspended above them (AD50 + AD0 insert) compared to when AD50 
cultures were suspended above them (AD50 + AD50 inserts). These data suggest that the 
presence of preadipocytes enhanced the increase of inflammatory gene expression in 
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AD50 cultures by 10,12 CLA treatment, once again suggesting cross-talk between 
preadipocytes and adipocytes. Therefore, a fourth model, the Conditioned Media (CM) 
Model, was implemented to clarify which cultures, AD50 or AD0, are responsible for 
10,12 CLA-mediated inflammation.  
 
Conditioned Media (CM) Model 
 Adipocytes Secrete Inflammatory Signals that Activate Preadipocytes-  This fourth 
model, as described in the Methods section and shown in Fig. 3.6A, was developed to 
better understand the inflammatory capacity of adipocytes vs. preadipocytes as well as 
crosstalk between both cell-types. It can be inferred from the Co-Culture Insert Model 
that cross-talk occurs between adipocytes and preadipocytes, as evidenced by the increase 
in inflammatory gene expression in AD50 cultures when AD0-containing inserts are 
suspended above them. Data from the Cell Separation Model also suggest that cross-talk 
occurs between adipocytes and preadipocytes. Therefor , we hypothesized that CM from 
10,12 CLA-treated AD50, but not AD0 cultures, would promote inflammatory protein 
activation and gene expression in naïve AD0 and AD50 cultures.  
 CM was collected from AD50 and AD0 cultures treated with 50 µM 10,12 CLA or 
BSA vehicle for 24 h.  A 24 h time point was chosen based on previous dose data 
showing that the secretion of IL-8, IL-6, and PGF2α by 24 h after 10,12 CLA treatment 
was greater than earlier time points in mixed cultures (36, 37). As hypothesized, CM 
from 10,12 CLA-treated AD50 cultures increased IL-8 and IL-6 gene expression in naïve 
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AD50 and AD0 cultures (Fig. 3.6B). MCP-1 and ATF3 gene expression were also 
increased in naïve AD0 and AD50 cultures by CM from 10,12 CLA-treated AD50 (data 
not shown). In contrast, CM from CLA-treated AD0 cultures did not increase 
inflammatory gene expression in naïve AD50 or AD0 cultures. Notably, CM from 10,12 
CLA-treated AD50 cultures caused a greater level of inflammatory gene expression in 
naïve AD0 vs. AD50 cultures. 
 Consistent with data in Fig. 3.6B, CM from AD50 cultures treated with 10,12 CLA 
vs. BSA vehicle increased P-ERK, P-JNK, and P-38 in naïve AD0 and AD50 cultures 
(Fig. 3.6C).  Next, we wanted to determine the extent to which CM from AD0 compared 
to AD50 cultures treated with 10,12 CLA for 15 min impacted MAPK phosphorylation.  
As hypothesized, CM from AD50 cultures increased the P-ERK, P-JNK, and P-p38, 
particularly in naive AD0 cultures compared to naïve AD50 cultures (Fig. 3.6D).  In 
contrast, CM from AD0 cultures did not increase the levels of P-ERK, P-JNK, or P-p38 
in either set of cultures.  Collectively, these data suggest that 10,12 CLA selectively 
activates adipocytes that secrete inflammatory adipocytokines, PGs, or free fatty acids 
(FFA) that signal to preadipocytes, resulting in increased inflammatory protein activation 
and gene expression in preadipocytes. 
 Therefore, we wanted to identify inflammatory candidates in the CM from cultures 
treated with 10,12 CLA. IL-6 and IL-8 levels (Fig. 3.7A) as well as PGF2 and PGE2 (Fig. 
3.7B) were higher in CM from 10,12 CLA-treated AD50 cultures, but not in AD0 
cultures compared to BSA controls. However, the increase in PGE2 in AD50 cultures was 
not higher than basal levels found in AD0 cultures. Consistent with the PGF2 data, iso-
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prostane F2 levels were higher in AD50 cultures treated with 10,12 CLA compared to 
BSA controls (Fig. 3.7C).  
 Due to the role that elevated FFA play in inducing i flammation and insulin 
resistance, we suspected that 10,12 CLA-mediated lipolysis may also be contributing 
inflammatory FFAs to the CM. Surprisingly, 10,12 CLA treatment increased [14C]-oleic 
acid release from AD0 cultures at 9 h (Fig. 3.7D) and 24 h (data not shown), but had no 
effect on AD50 cultures. These data suggest that 10,12 CLA-driven lipolytic activity does 
not contribute to the inflammatory capacity of AD50 CM.  
 In order to determine if adipocytokines are necessary for the inflammatory capacity of 
AD50 CM, AD50 cultures were pretreated with 1 µg/ml brefeldin A (BA) for 1 h to 
prevent cytokine secretion by inhibiting protein transport from the ER to the golgi 
apparatus. Subsequently, cultures were treated with 50 µM CLA or BSA for 24 h, after 
which CM was collected and added to naïve AD0 or AD50 cultures (at a 1:1 ratio) for 3 h 
and cells were harvested to measure inflammatory gene expression. As hypothesized, BA 
pretreatment prevented CLA-mediated adipocytokine secretion (Fig. 3.8A). Furthermore, 
pretreatment with BA prevented AD50 CM-mediated increases of IL-8 and IL-6 mRNA 
levels in AD0 and AD50 cultures (Fig. 3.8B). Similar effects were found for MCP-1 and 
ATF-3 gene expression (data not shown).   
 In order to more specifically identify inflammatory adipocytokines or PGs 
responsible for mediating inflammatory signaling in AD0 cultures, IL-8, IL-6, and PGF2α 
were targeted for further investigation. IL-8 α and β receptors, IL-6 receptor and signal 
transducer (ST), and PGF2α receptor expression were measured in our primary cultures of 
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human preadipocytes. Consistent with a previous report (42), IL-8 α and β receptors were 
undetectable in human preadipocytes (data not shown). Interestingly, IL-6 receptor and 
ST and PGF2α receptor expression were higher in AD0 vs. AD50 cultures (Fig. 3.9A).  
Consequently, AD50 cultures were pretreated with an IL-6 neutralizing ab or the FP 
prostanoid receptor antagonist AL-8810 for 30 min and subsequently treated with 10,12 
CLA or BSA vehicle for 24 h. First, AD50 cultures were analyzed for inflammatory 
mRNA levels. Whereas there was no effect of 0.01 µg/ml IL-6 ab on IL-8 mRNA levels, 
50 µM AL-8810 prevented CLA induction of IL-8 in AD50 cultures (Fig. 3.9B). Next, 
CM from these AD50 treated cultures was collected an  dded to AD0 cultures at a 1:1 
ratio, after which IL-8 gene expression was measured at 3 h and P-STAT3, P-ERK, and 
P-JNK levels were measured at 1 h. IL-6 neutralizing ab and AL-8810 attenuated IL-8 
gene expression (Fig. 3.9B), but not other inflammatory genes induced by CLA CM 
including IL-6 and MCP-1 (data not shown). Neutralizing IL-6 attenuated P-STAT3 
levels in a dose-dependent manner (Fig. 3.9C).  However, only 0.1 µg/ml IL-6 
neutralizing ab modestly attenuated P-ERK and P-JNK levels increased by CLA CM. As 
expected, AL-8810 had no effect on P-STAT3 levels, but 10 µM AL-8810 reduced P-
JNK levels, and modestly reduced P-ERK levels (Fig. 3.9C). The specificity of the IL-6 
neutralizing ab and AL-8810 was confirmed (Fig. 3.9D). The IL-6 ab dose-dependently 
reduced IL-6-mediated increases in P-STAT3 and P-ERK levels, and AL-8810 dose-
dependently reduced PGF2α-mediated increases in P-ERK levels. These data sugge t that 
IL-6 and PGF2α contribute, in part, to the inflammatory capacity of CLA CM from AD50 
cultures.  Taken together, these data imply that adipocytes instigate the inflammatory 
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response to 10,12 CLA treatment in newly differentiated cultures of primary human 
adipocytes, which in turn activate inflammatory pathways in neighboring preadipocytes 
(Fig. 3.10).  
 
Discussion 
 Interpretation of Data from the Four Cell Models- We demonstrated using four 
experimental models, that adipocytes are the instigators of 10,12 CLA-induced 
inflammation in primary cultures of newly differentiated human adipocytes. Data from 
the Differentiation Model showed that 10,12 CLA-induced inflammatory signaling was 
greater in differentiated cultures (AD10-50) compared to undifferentiated cultures (AD0) 
as evidenced by increased expression of inflammatory genes and phosphorylation of 
MAPK and AP-1.  Results from the Cell Separation Model suggest that adipocytes signal 
to preadipocytes during treatment with 10,12 CLA in mixed cultures (AD30), as there 
was an increase in inflammatory gene expression in the PDF, yet no induction of 
inflammatory genes in cultures containing only preadipocytes (AD0) as shown in the 
Differentiation and Co-Culture Insert Models.  Next, it was demonstrated in the Co-
Culture Insert Model that not only are adipocytes rquired for an inflammatory response 
to CLA, but that preadipocytes also enhance the inflammatory response in differentiated 
cultures to 10,12 CLA treatment. Finally, using the Conditioned Media Model, we 
demonstrated that CM from differentiated cultures (AD50), but not undifferentiated 
cultures (AD0), treated with 10,12 CLA yielded bioactive CM containing inflammatory 
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adipocytokines and PGs that promote increased inflamm tory signaling in naïve 
(pre)adipocytes. Notably, CM from the differentiated cultures caused greater increases in 
inflammatory gene expression in preadipocytes (AD0) vs. adipocytes (AD50). Blocking 
adipocytokine release with brefeldin A prevented CLA CM induction of IL-6, IL-8, and 
MCP-1 Moreover, neutralizing IL-6 and blocking the PGF2α receptor attenuated CLA 
CM-induced IL-8 gene expression or STAT3 phosphorylation in preadipocytes. 
However, other genes induced by CLA CM including IL-6 and MCP-1 were not affected. 
Therefore, IL-6 and PGF2α may be key factors in CM contributing to the inflammatory 
response in preadipocytes, but likely are not solely r sponsible.  Further investigation is 
needed to determine other important inflammatory mediators in CLA CM and potential 
synergism of these bioactive factors. Taken together, t se studies show that adipocytes 
are the main initiators of 10,12 CLA-mediated inflammatory signaling in primary 
cultures of newly differentiated human adipocytes.   
 Cell Types in WAT and Their Inflammatory Capacity-  Adult human WAT has been 
reported to contain ~50-70% adipocytes, ~ 20-40% preadipocytes, and ~1-30% infiltrated 
macrophages (43, 44).  These percentages depend on body composition and age. For 
example, it has been reported that WAT of lean women contain ~30% preadipocytes, 
whereas WAT of obese women contain only 17% preadipocytes (45). However, the 
localization and secretory pattern of cytokines in WAT are unknown. Some researchers 
suggest that non-fat cells such as macrophages are the key players in cytokine release 
from adipose tissue (46, 47).  According to Fain et al. 2004, non-fat cells are responsible 
for up to 90% of adipokine release from WAT compared to mature adipocytes. These 
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samples, obtained from obese women directly after undergoing bariatric surgery, were 
analyzed for basal levels of inflammatory markers.  Similarly, results from our lab 
suggested that 10,12 CLA-mediated cytokine release was predominately from SV cells 
freshly isolated from human subcutaneous WAT as opposed to cultured newly 
differentiated adipocytes (23, 36). However, this heterogeneous mixture of SV cells had 
never been exposed to adipocyte media (AM-1) for 6-12 d as in the current study.  Thus, 
we do not know if these SV cultures contained cells other than preadipocytes (i.e., 
macrophages) that may respond differently to CLA.   
 In contrast to these studies, our current results show that cultured preadipocytes 
grown in adipocyte media do not secrete adipocytokines in response to 10,12 CLA 
treatment, suggesting that the microenvironment of cultured (pre)adipocytes may affect 
experimental outcomes. For example, it has been proposed that adipocyte size is an 
important determinant of adipokine secretion, where proinflammatory cytokine secretion 
(i.e., IL-6, IL-8, MCP-1, TNFα) was higher from large adipocytes compared to smaller 
adipocytes (48). Interestingly, Suganami et al. (49, 50) reported that activated 
hypertrophied adipocytes release saturated free fatty acids that subsequently promote 
TNFα secretion from macrophages, leading to an inflammatory cycle in adipose tissue. 
Taken together, these results suggest that differenc s in the inflammatory capacity of 
preadipocytes, adipocytes, or other inflammatory cells like macrophages in WAT may be 
due to 1) the type of inflammatory stimuli employed, 2) the microenvironment of 
cultures, 3) adipocyte size, 4) degree of adiposity, or 5) crosstalk with other cell types. 
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 Shortcomings of Cell Models-  Due to our use of primary SV cells, it is difficult to 
achieve fully-differentiated cultures containing 100% adipocytes (AD100). Our greatest 
level of differentiation was approximately 50% adipocytes (AD50) on days 8-12. 
Therefore, it is difficult to clearly ascertain the function of adipocytes alone, being that 
preadipocytes are always present in our cultures. The Cell Separation Model provides us 
the ability to separately analyze inflammatory gene expression from each fraction.  
However, these cells have direct cell-to-cell contact during treatment. The Insert Model 
provides an environment where these cells are not i direct contact. Yet, the most 
differentiated cultures still contain ~50% adipocytes. Therefore, future studies are needed 
to determine the effect of CLA on pure cultures of mature adipocytes. These could be 
achieved by 1) developing a more effective differentiation cocktail, 2) using freshly 
isolated floating adipocytes during the isolation of SV cells, or 3) using fully 
differentiated cultures of murine 3T3-L1 adipocytes.  Another challenge with using 
primary human adipocytes is that the degree of differentiation varies between 
experiments.  
 Although there are some limitations in using primary cultures, our model of primary 
cultures of newly differentiated human adipocytes is a particular strength due to its direct 
application to (pre)adipocytes in human WAT compared to using animal (pre)adipocytes 
or cell lines of adipocytes. This model also allows us to examine the direct effects of 
CLA on cross-talk between preadipocytes and adipocytes as occurs in vivo, and their 
impact on cell signaling, gene expression, and metabolism.   
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 Implications and Future Experiments- Results presented in this manuscript clearly 
show that adipocytes are essential for the inflammatory response to CLA. On the basis of 
these studies, we propose that treating primary cultures of newly differentiated human 
adipocytes with 10,12 CLA increases the phosphorylation of MAPK (i.e., ERK 1/2, JNK, 
and p38) and the activation of the transcription factor AP-1 (i.e., c-Jun and ATF3), which 
leads to the production of inflammatory adipocytokines and PGs through upregulating 
inflammatory genes (i.e., COX-2, IL-6, IL-1β, IL-8, MCP-1, and ATF3). These 
inflammatory signals subsequently activate preadipocytes, leading to inflammatory 
cytokine secretion from preadipocytes, thus continuing the inflammatory cycle. These 
studies are expected to lead to discovering the earliest mechanism by which 10,12 CLA 
causes adipocyte delipidation.  As a consequence, it will enable researchers to determine 
the potentially-safe and effective use of CLA as a dietary strategy to promote weight loss.  
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FIGURE 3.1. The percentage of lipid-filled adipocytes increases with the duration of 
BRL supplementation.  Four human (pre)adipocyte cell models containing ~ 0, 10, 30, 
and 50% adipocytes were established by modulating exposure to DM-1. AD0 cultures 
received no DM-1 for 8 d (NT). AD10, AD30, and AD50 cultures were supplemented 
with DM-1 containing 1 µM BRL and 250 µM IBMX for 5 h, 3 d, or 6 d, respectively. A) 
On d 9-10, cells were fixed with baker’s formalin, stained with ORO to detect adipocytes, 
and counter-stained with Mayer’s Hematoxylin to detect non-differentiated cells. Three 
pictures per well were taken, each of a different field. B) The total number of cells 
stained with ORO were counted and expressed as a percentage of total cell number.  C) 
TG content was determined using a colorimetric assay. D ta are expressed as µg TG/ µg 
DNA. Data in panels A-C are representative of three independent experiments. Means ± 
SEM not sharing a common superscript differ significantly (p < 0.05). 
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FIGURE 3.2. 10,12 CLA-induction of inflammatory gene expression increases as the 
degree of differentiation increases. Using the Differentiation Model, each experimental 
group (i.e., AD0, AD10, AD30, and AD50) was treated with BSA vehicle, 50 µM 10,12 
CLA or 50 µM 9,11 CLA as a positive control for 12 h. Cells were harvested for RNA 
extraction and mRNA analyses via qPCR on d 9 for subsequent analysis of A) marker 
gene analyses to verify increases in adipocyte number with increasing duration of DM-1 
treatment and B) inflammatory genes increased by 10,12 CLA compared to 9,11 CLA 
and BSA controls. Data were normalized to BSA vehicl  in AD0 cultures. Means ± SEM 
(n = 3) not sharing a common superscript are significantly different (p < 0.05). Data in 
panels A and B are representative of three independent experiments.  
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FIGURE 3.3. Time-dependent increase in the activation of MAPK and transcription 
factors in AD50 vs. AD0 cultures treated with 10,12 CLA.  AD0 and AD50 cultures 
were treated with 50 µM 10,12 CLA (C) or BSA (B) control for 6, 12, or 24 h. Cells were 
harvested and analyzed for protein expression via immunoblot. Membranes were probed 
with antibodies targeting A) phospho (P)- and total ERK, JNK, and p38, and B) P-c-Jun, 
c-Jun, ATF3, and GAPDH (n = 2). Data in panels A and B are representative of three 
independent experiments.   
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FIGURE 3.4. 10,12 CLA induces inflammatory gene expression in the PDF and 
ADF fractions of newly differentiated primary human adipocytes. A) Human SV 
cells were supplemented with 1 µM BRL for 3 d yielding cultures containing ~ 30% 
adipocytes (AD30). Cultures were treated with 50 µM10,12 CLA or BSA vehicle for 12 
h and next fractionated using 6% iodixanol (1.03 g/ml). The lipid-laden ADF was floated, 
and the PDF was pelleted. B) Fractionations were verified by measuring gene expression 
of AEBP-1, aP2, and apm1 using qPCR. C) Relative mRNA expression of IL-8, IL-1β, 
COX-2, and ATF3 were investigated using qPCR. Data in panels B-C were normalized 
to BSA vehicle in the PDF. Means ± SEM (n = 3) not sharing a common superscript 
differ significantly (p < 0.05). Data in panels B and C are representative of three 
independent experiments.  
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FIGURE 3.5. 10,12 CLA-induced inflammatory gene expression is greatest in AD50 
cultures in the presence of AD0-containing inserts. A) Inserts containing either 
preadipocytes (AD0) or preadipocytes and adipocytes (AD50) were suspended over 6-
well plates containing either AD0 or AD50 cultures. B) Next, both wells and inserts were 
supplemented with 50 µM 10,12 CLA or BSA vehicle control for 12 h and inflammatory 
gene expression in the cells in the underlying wells were subsequently analyzed via 
qPCR. Means ± SEM (n = 3) not sharing a common super cript differ significantly (p < 
0.05). Data are representative of two independent experiments. 
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FIGURE 3.6. CM from 10,12 CLA-treated AD50 cultures induces inflammatory 
genes and activates MAPK in naïve AD0 and AD50 cultures. A) CM was collected 
from AD0 and AD50 cultures that were treated with 50 µM 10,12 CLA or BSA control 
for 24 h. A 1:1 ratio of CM and AM-1 was added to AD0 and AD50 cultures for 3 h. B) 
Next, inflammatory genes were analyzed via qPCR. Means ± SEM (n = 4) not sharing a 
common superscript differ significantly (p < 0.05). C)  AD0 and AD50 cultures were 
treated with AD50 CM for 15 min, 1 h, and 3h. D) AD0 cultures were treated with AD50 
and AD0 CM for 15 min.  C-D) Cells were harvested and analyzed for protein expression 
via immunobloting. Membranes were probed with antibod es targeting P- and total ERK, 
JNK, and p38 (n = 2).  Data in panels B-D are representative of three independent 
experiments. 
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FIGURE 3.7. 10,12 CLA-treated AD50 cultures secrete adipocytokines and PGF2. 
Cells were treated with 50 µM 10,12 CLA or BSA contr l for 24 h. A) CM was collected 
and IL-8 and IL-6 were measured in CM using BioRad’s BioPlex suspension array 
system. B) CM was collected and PGF2 and PGE2 were measured using a stable isotope 
dilution GC/NICI/MS assay. C) Cells were harvested in PBS and total F2-IsoProstanes 
were measured using GC/MS with selective ion monitori g. D) AD0 and AD50 cultures 
were treated with 20 µl HBSS containing 12.5 nM [14C]-oleic acid (0.2 µCi; specific 
activity = 40-60 mCi/mmol) for 12 h. Media was removed and cells were washed three 
times with HBSS containing 2% BSA. Subsequently, each well was treated with 250 µl 
DMEM containing 50 µM 10,12 CLA or BSA + phloretin, a fatty acid uptake inhibitor, 
for 9 h. 200 µl media was collected from each well and measured for [14C]-oleic acid by 
scintillation counting. Means ± SEM (n = 4 A-C; n = 3 D) not sharing a common 
superscript differ significantly (p < 0.05). Data in panels A-C and in panel D are 
representative of two or three independent experiments, respectively.  
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FIGURE 3.8.  Brefeldin A (BA) prevents CM from 10,12 CLA AD50 cultures from 
inducing inflammatory gene expression. AD50 cultures were pretreated with 1 µg/ml 
BA for 1 h to prevent cytokine secretion, and treated with 50 µM CLA or BSA for 24 h. 
A) IL-8 and IL-6 were measured in CM using BioRad’s BioPlex suspension array 
system. B) CM was collected and 1 mL was added to naïve AD0 or AD50 cultures 
containing 1 mL of AM-1 (1:1 ratio) for 3 h and cells were harvested to measure 
inflammatory gene expression via qPCR. Means ± SEM (n = 2 A; n = 3 B) not sharing a 
common superscript differ significantly (p < 0.05). Data in panel A and B are 
representative of two or three independent experiments, respectively. 
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FIGURE 3.9. IL-6 neutralizing antibody (IL-6 ab) and PGF2α analog and FP 
prostanoid receptor antagonist, AL-8810, attenuate CLA CM-induced IL-8 gene 
expression and P-STAT3 levels.  A) AD0 and AD50 cultures treated with BSA or CLA 
CM at a 1:1 ratio of CM to AM-1 for 3 h were analyzed for IL-6 receptor (R), IL-6 signal 
transducer (ST), and PGF2α R expression via qPCR. B) AD50 cultures were pretreated 
with 0.01 ug/ml IL-6 ab or 50 µM AL-8810 for 30 min, and subsequently treated with 50 
µM 10,12 CLA or BSA vehicle for 24 h, after which IL-8 mRNA levels were measured. 
Next, AD0 cultures were treated with AD50 CM for 3 h and IL-8 mRNA levels were 
measured. C) AD50 cultures were pretreated with 0.01, 0.1, and1 µg/ml IL-6 ab or 1 and 
10 µM AL-8810 for 30 min. Then cultures were treated with 50 µM 10,12 CLA or BSA 
vehicle for 24 h, after which CM was collected and added to AD0 cultures for 1 h. 
Cultures were treated with 0.1 µg/ml recombinant human (rh) IL-6 and 10 µM PGF2α 
(PG) for 30 min as positive controls. D) AD0 cultures were pretreated with 0.01, 0.1, 1, 
or 10 µg/ml IL-6 ab or 0.5, 5, or 50 µM AL-8810 for 30 min, and subsequently treated 
with 0.1 µg/ml rh IL-6 or 10 µM PG for 30 min, respctively. C-D) Cells were harvested 
and analyzed for levels of P- and total STAT3, ERK, or JNK via immunoblotting. Means 
± SEM (n = 3 A; n = 2-3 B-D) not sharing a common superscript differ significantly (p < 
0.05).  Data in panels A-D are representative of three independent experiments.  
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FIGURE 3.10. Working Model. Treating primary cultures of newly differentiated 
human adipocytes with 10,12 CLA increases the phosprylation of MAPK (i.e., ERK 
1/2, JNK, and p38) and the activation of the transcription factor AP-1 (i.e., c-Jun, c-Fos, 
ATF2, and ATF3), which leads to the production of inflammatory cytokines and PGs 
(i.e., PGE2, PGF2) through upregulating inflammatory genes (i.e., COX-2, IL-1β, IL-8, 
and ATF3). These inflammatory signals subsequently activate preadipocytes, leading to 
inflammatory cytokine secretion from preadipocytes, thus continuing the inflammatory 
cycle.  Furthermore, activation of STAT3, MAPK, and AP-1 by 10,12 CLA antagonizes 
PPARγ and associated target genes, ultimately leading to delipidation through decreased 
glucose and fatty acid uptake and TG content in adipocytes. 
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CHAPTER IV 
 
SP600125 ATTENUATES TRANS-10, CIS-12 CONJUGATED LINOLEIC ACID- 
MEDIATED REGULATION OF INFLAMMATORY AND LIPOGENIC GENE 
EXPRESSION 
 
  
Abstract 
 
Supplementation with a mixture of trans-10, cis-12 (t10,c12) and cis-9, trans-11 (c9,t11) 
isomers of conjugated linoleic acid (CLA), or t10,c12 CLA alone, reduces body weight 
and fat deposition in animals and some humans.  However, these anti-obesity actions of 
t10,c12 CLA are routinely accompanied by increased markers of inflammation and 
insulin resistance. Thus, we examined the extent to which blocking c-Jun NH2-terminal 
kinase (JNK) signaling using the JNK inhibitor SP600125 attenuated markers of 
inflammation and insulin resistance in primary human adipocytes treated with t10,c12 
CLA. SP600125 attenuated t10,c12 CLA-mediated phosprylation of cJun and 
increased protein levels of activating transcription factor (ATF) 3, two downstream 
targets of JNK.  SP600125 attenuated t10,c12 CLA-mediat d induction of inflammatory 
genes, including interleukin (IL)-6, IL-8, IL-1β, ATF3, monocyte chemoattractant protein 
(MCP)-1, and cyclooxygenase-2.  Consistent with these data, SP600125 prevented 
t10,c12 CLA-mediated secretion of IL-8, IL-6, and MCP-1.  SP600125 prevented t10,c12 
78 
 
CLA suppression of lipogenic genes including peroxis me proliferator activated receptor 
gamma, liver x receptor, sterol regulatory element binding protein, acetyl-CoA 
carboxylase, and stearoyl-CoA desaturase.  Additionally, SP600125 blocked t10,c12 
CLA-mediated induction of suppresser of cytokine synthesis-3 and suppression of 
adiponectin and insulin-dependent glucose transporter 4 mRNA levels.  Collectively, 
these data suggest that JNK signaling plays an important role in t10,c12 CLA-mediated 
regulation of inflammatory and lipogenic gene expression in primary cultures of human 
adipocytes.   
 
Introduction 
Obesity is a global health issue with ~ 500 million people classified as obese and 1.5 
billion overweight in 2008, including 43 million children under the age of five reported in 
2010 [1].  One potential strategy for reducing adipos ty is consumption of conjugated 
linoleic acid (CLA), unsaturated fatty acids found i  ruminant meats and dairy products, 
or in dietary supplements and fortified foods. Conjugated linoleic acid refers to a group 
of conjugated octadecadienoic acid isomers derived from linoleic acid, a fatty acid that 
contains 18 carbons and 2 double bonds in cis configuration at the 9th and 12th carbons 
(i.e., cis-9, cis-12 octadecadienoic acid). Microbes in the gastrointestinal tract of ruminant 
animals convert linoleic acid into different isoforms of CLA through biohydrogenation. 
This process changes the position and configuration of the double bonds, resulting in a 
single bond between one or both of the two double bonds (i.e., cis-9, trans-11 (c9,t11) or 
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trans-10, cis-12 (t10,c12) octadecadienoic acid). Consuming a mixture of c9,t11 and 
t10,c12 CLA isomers, or t10,c12 CLA alone, reduces body fat mass in rodents, 
particularly mice, and some humans [reviewed in 2]. However, the isomer-specific 
mechanism by which CLA reduces adiposity is unclear.  Furthermore, a number of 
clinical studies report potential side effects of CLA supplementation including increased 
levels of markers of inflammation (e.g., inflammatory cytokines, chemokines, or 
prostaglandins), insulin resistance, hyperlipidemia, and lipodystrophy [3-7]. These anti-
obesity and adverse side effects of CLA appear to be due primarily to the t10,c12 isomer.   
In contrast, the c9,t11 isomer appears to have anti-inflammatory and anti-diabetic 
properties without reducing body weight [8].  
 We have demonstrated that t10,c12 CLA reduces glucose and fatty acid uptake and  
triglyceride content in cultures of human adipocytes, in part, by activating extracellular 
signal-related kinase (ERK) [9] and nuclear factor kappa B (NFκB) [10].  These in vitro 
data have been confirmed in vivo [11]. Activated NFκB [12-14] and ERK [15-17] induce 
markers of inflammation and antagonize peroxisome proliferator activated receptor 
(PPAR)γ activity, thereby causing insulin resistance.  However, the extent to which 
t10,c12 CLA activates other kinases or transcription factors that impact inflammatory 
signaling, insulin sensitivity, and triglyceride content in human adipocytes, and their 
mechanism of action, are unclear.   
 We recently demonstrated that t10,c12 CLA increased th  phosphorylation levels of 
c-Jun NH2-terminal kinase (JNK) and downstream targets cJun and activating 
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transcription factor (ATF3), members of the redox-sensitive transcription factor 
activating protein-1 (AP-1), that induce inflammatory gene transcription [18-19]. c-Jun 
NH2-terminal kinase activation is known to enhance inflammation and insulin resistance 
associated with obesity, and lack of JNK1 or JNK2 reduces body fat and improves insulin 
sensitivity in vivo [20-21] and in vitro [22]. However, the role of JNK in activating cJun 
or ATF3 in CLA-treated cultures and the extent to which this activation regulates 
inflammatory and lipogenic gene expression has not been investigated. 
 Based on these data, we hypothesized that JNK plays an important role in t10,c12 
CLA-mediated activation of AP-1 and induction of inlammatory genes and suppression 
of lipogenic genes. To test this hypothesis, we employed the chemical JNK1-3 inhibitor, 
SP600125. By using this inhibitor, we demonstrate that JNK is involved in the regulation 
of t10,c12 CLA-induced inflammatory signaling, and suppression of gene markers for 
adipogenesis, lipogenesis, and insulin signaling in cultures of newly-differentiated human 
adipocytes.  Therefore, JNK may be an important target for preventing 10,12 CLA-
mediated inflammation.                                                              
 
Materials and Methods 
Materials   
All cell culture ware were purchased from Fisher Scientific (Norcross, GA). Lightning 
Chemiluminescence Substrate was purchased from Perkin Elmer Life Science (Boston, 
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MA).  Immunoblotting buffers and precast gels were purchased from Invitrogen 
(Carlsbad, CA). Adipocyte media was purchased from Zen Bio (Research Triangle Park, 
NC). The Nuclear Extract Kit was purchased from Active Motif (Carlsbad, CA). 
Polyclonal antibodies for anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
ATF3 and monoclonal antibody for anti-PPARγ were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Anti-total and anti-phospho (P) JNK (Thr183/Try185) 
and P-cJun (Ser63) antibodies were purchased from Cell Signaling Technologies 
(Beverly, MA). Anti-nucleoporin was purchased from BD transduction laboratories (San 
Jose, CA). Hyclone fetal bovine serum was purchased from Fisher Scientific. Isomers of 
CLA (+98% pure) were purchased from Matreya (Pleasant Gap, PA). The cell permeable 
selective JNK1-3 inhibitor SP600125 (#420119; Anthra[1,9-cd]pyrazol-6(2H)-one, 1,9-
pyrazoloanthrone; JNKII) was purchased from EMD Chemicals (Gibbstown, NJ). This 
inhibitor of JNK1-3 is competitive with respect to ATP, and has over a 300-fold greater 
selectivity for JNK compared to other mitogen-activa ed protein kinase (MAPK) 
including ERK and p38 [23], and specifically inhibits the phosphorylation of cJun serine 
residues 63 and 67 [24].  All other reagents and chemicals were purchased from Sigma 
Chemical Co. (St. Louis, MO) unless otherwise stated. 
 
Culturing of human primary adipocytes   
Abdominal white adipose tissue was obtained with consent from the Institutional Review 
Boards at the University of North Carolina at Greensboro and the Moses Cone Memorial 
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Hospital, during elective abdominoplasty of non-diabetic Caucasian and African 
American females between the ages of 20-50 years old with a body mass index ≤ 32.0. 
These selection criteria allow for reduced variation n gender, age, and obesity status. 
Tissue was digested using collagenase; stromal vascular ells were isolated as previously 
described [9].  Stromal vascular cells were differentiated with adipocyte media (AM-1) 
containing 1 µM rosiglitazone and 250 µM 1-methyl-3-isobutylxanthine for 3 d, which 
yielded cultures containing ~30-50% adipocytes. On days 6-12, cells were pretreated 
with 5, 20, or 80 µM SP600125 JNK inhibitor dissolved in DMSO for 30 min, and 
subsequently treated with 50 µM t10,c12 CLA or bovine serum albumin (BSA) vehicle 
control for 12-24 h depending on the experimental outc me measured. All cultures were 
normalized to contain the same amount of BSA and DMSO vehicles. Each independent 
experiment was repeated at least twice using a mixture of cells from three subjects, unless 
otherwise indicated. 
 
Fatty acid preparation 
t10,c12 CLA was delivered as a free acid complexed to 7.5% fatty acid-free BSA at a 4:1 
molar ratio as previously described [9].  
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RNA isolation and PCR   
Total RNA was isolated from the cultures using Tri Reagent purchased from Molecular 
Research Center (Cincinnati, OH), according to manufact rer’s protocol.  For quantitative 
real time PCR, 2.0 ug total RNA was converted into first strand cDNA using Applied 
Biosystems High-Capacity cDNA Archive Kit (Foster City, CA).  Real time PCR was 
performed in an Applied Biosystems 7500 FAST Real Time PCR System using Taqman 
Gene Expression Assays.  To account for possible variation in cDNA input or the 
presence of PCR inhibitors, the endogenous referenc gene GAPDH was simultaneously 
quantified for each sample, and these data normalized accordingly. The Relative Standard 
Curve Method using seven, two-fold dilutions ranging from 100 – 1.56 ng RNA was used 
to check primer efficiency and linearity of each transcript according to Applied 
Biosystem’s Guide to Performing Relative Quantification of Gene Expression Using 
Real-Time Quantitative PCR.  
 
Nuclear and cytosolic separation   
Nuclear and cytosolic cellular fractions were prepad using a commercially available kit 
from Active Motif as previously described [10]. 
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Immunoblotting   
Immunoblotting using 20 ug of protein per lane was conducted using 4-12% NuPage 
precasted gels (Invitrogen) as previously described [10]. Briefly, PVDF membranes were 
blocked with 5% milk in TBST for 1 h and washed 3 x in TBST for 5 min. Blots were 
incubated overnight at 4°C with primary antibodies targeting P-JNK, P-cJun, total cJun, 
and ATF3 at a dilution of 1:1000, and subsequently incubated in the respective 
horseradish peroxidase-conjugated secondary antibody at a dilution of 1:5000 at room 
temperature for 1 h. Primary and secondary antibodies targeting GAPDH were used at a 
1:5000 dilution. Primary and secondary antibodies targeting PPARγ were used at 
dilutions 1:200 and 1:2000, respectively. After washing, blots were treated with 
chemiluminescence reagent for 1 min and film was exposed using a SRX-101A Konica 
Minolta flim developer. Densitometry was performed using a Kodak Image Station 440 
CF by Perkin Elmer and Kodak Molecular Imaging Software Version 4.0.   
 
Secretion of IL-6, IL-8, and monocyte chemoattractant protein (MCP)-1  
The concentrations of IL-6, IL-8, and MCP-1 were determined using the BioPlex® 
Suspension Array System from Bio-Rad (Hercules, CA) following the manufacturer’s 
protocol.  Briefly, media was collected from cultures that were pretreated with 5, 20, or 
80 µM SP600125 for 30 min, and subsequently treated with 50 µM t10,c12 CLA or BSA 
for 24 h. The media was centrifuged at 13,200 x g for 10 min at 4°C to clear the samples 
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of any precipitate. Samples and standards were run in duplicate. Based on the 
manufacturer’s report ‘Bio-Plex Pro Human Cytokine, Chemokine, and Growth Factor 
Assays - Bulletin 5828,’ the intra-assay % CVs for IL-6, IL-8, and MCP-1 are 7, 9, and 
9%, respectively. The inter-assay % CVs are 11, 4, and 7%, respectively.  
 
Statistical analyses   
Data are expressed as the means ± S.E. Data were analyzed using one-way analysis of 
variance followed by Tukey’s-HSD tests for each pair for multiple comparisons.  
Differences were considered significant if p < 0.05.  All analyses were performed using 
JMP IN, Version 9 Software (SAS Institute, Cary, NC). 
 
Results 
The JNK inhibitor SP600125 attenuates t10,c12 CLA-mediated activation of cJun 
and ATF3  
We previously demonstrated that treatment of newly-differentiated human adipocytes 
with 50 µM t10,c12 CLA, but not c9,t11 CLA, for 6 h increased phosphorylation levels 
of JNK and cJun, which was sustained for 24 h when compared to vehicle (BSA)-treated 
cultures in total cell extract [18-19]. However, a direct role for JNK in the activation of 
cJun and upregulation of inflammatory genes in respon e to t10,c12 CLA treatment has 
not been determined. In order to implicate a role fr JNK in the activation of cJun, we 
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examined JNK and cJun phosphorylation in cytosol and nuclear fractions after 6, 12, and 
24 h of treatment with t10,c12 CLA. Phosphorylation of JNK was increased at 6 h and 
was sustained at 24 h in the cytosolic fraction, and increased in the nuclear fraction at 12 
and 24 h with t10,c12 CLA. Interestingly, t10,c12 CLA increased total cJun levels 
compared to the BSA control in the nuclear fraction at all time points. Consistently, cJun 
phosphorylation by t10,c12 CLA was detected almost exclusively in the nuclear fraction 
at all time points (Fig. 1a). Based on the robust t10,c12 CLA-mediated activation of JNK 
and cJun, we investigated the extent to which pretreatment with the JNK inhibitor 
SP600125 blocked t10,c12 CLA--mediated phosphorylation of cJun after 12 h of 
treatment.  Concentrations of SP600125 ranging between 5-80 uM were chosen based on 
studies using Jurkat T cells in which the IC50 for blocking cJun phosphorylation was 10 
uM and using CD4+ cells isolated from human peripheral blood mononuclear cells in 
which the IC50 for blocking cyclooxygenase (COX)-2 and tumor necrosis factor alpha 
expression was 5 and 10 uM, respectively [23]. SP600125 suppressed t10,c12 CLA-
mediated phosphorylation of cJun and increase in the protein levels of ATF3, an AP-1 
family member, in total cell lysates (Fig. 1b). These data suggest that JNK is involved in 
t10,c12 CLA-mediated cJun activation.  
 
SP600125 attenuates t10,c12 CLA  induction of inflammatory genes   
Next, we determined the extent to which SP600125 blocked t10,c12 CLA-induced 
inflammatory gene expression.  Pretreatment of cultures with SP600125 attenuated 
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t10,c12 CLA-induction of IL-8, IL-6, IL-1β,  MCP-1, COX2, and ATF3  (Fig. 2a). 
Consistent with these data, SP600125 attenuated t10,c12 CLA-mediated secretion of IL-
8, IL-6, and MCP-1 (Fig. 2b). Collectively, these data demonstrate that SP600125 
suppresses t10,c12 CLA-mediated induction of inflammatory gene expression and protein 
secretion. 
 
SP600125 blocks t10,c12 CLA suppression of lipogenic genes 
Inflammatory transcription factors such as NFκB and AP-1 in concert with MAPKs like 
ERK have been shown to inhibit lipogenic gene expression, in part, by suppressing 
PPARγ activity [12-17].  Due to the hypothesized role of JNK in regulating t10,c12 CLA-
induced inflammation, we investigated the impact of SP600125 on t10,c12 CLA-
mediated suppression of lipogenic gene expression and PPARγ protein levels. Consistent 
with our hypothesis, SP600125 blocked t10,c12 CLA-mediated suppression of the 
expression of transcription factors that regulate lipid metabolism (i.e., PPARγ/α,  sterol 
regulatory element binding protein (SREBP)-1c, liver X receptor (LXR)α  and several of 
their downstream targets (i.e., acetyl-CoA carboxylase (ACC)-1, stearoyl-CoA desaturase 
(SCD)-1) in a concentration-dependent manner (Fig. 3a).  Additionally, 20 uM SP 
modestly prevented a CLA-mediated decrease in PPARγ protein levels (Fig. 3b). Taken 
together, these data suggest that JNK activity regulates t10,c12 CLA-mediated 
suppression of lipogenic genes, which may contribute to the ability of t10,c12 CLA to 
decrease the triglyceride levels in adipocytes. 
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SP600125 prevents t10,c12 CLA-mediated regulation of genes involved in insulin 
signaling   
We previously demonstrated that t10,c12 CLA-induced inflammation leads to a 
suppression of insulin signaling and sensitivity [9,10,18,19].  Therefore, we determined 
the extent to which JNK impacted the expression of genes associated with insulin 
signaling. SP600125 attenuated t10,c12 CLA-mediated induction of suppressor of 
cytokine synthesis (SOCS)-3, a protein reported to cause insulin resistance (Fig. 4).  
Consistent with these data, t10,c12 CLA-mediated suppression of insulin-dependent 
glucose transporter (GLUT) 4 and adiponectin mRNA leve s, which are positively 
associated with insulin sensitivity, was attenuated by SP600125 in a concentration-
dependent manner (Fig. 4). Further studies are needed to confirm a role for JNK in CLA-
mediated suppression of insulin-stimulated glucose uptake. 
 
Discussion 
Consistent with our hypothesis, t10,c12 CLA-mediated activation of cJun and ATF3 were 
attenuated by the chemical JNK inhibitor, SP600125.  SP600125 also blocked t10,c12 
CLA-induced inflammatory gene expression and cytokine secretion, and suppression of 
lipogenic genes and markers of insulin signaling.  Taken together, these data suggest that 
JNK plays a role in t10,c12 CLA-mediated induction f markers of inflammation and 
insulin resistance in cultures of human adipocytes.  However, due to the potential lack of 
specificity of chemical inhibitors (i.e., they can inhibit other kinases including ERK and 
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p38, albeit at much lower selectivities [23]), JNK gene silencing experiments are needed 
to confirm these results.  Knockdown experiments are also need to determine the extent 
to which JNK signaling impairs insulin-stimulated glucose uptake in t10,c12 CLA-treated 
cultures, because such longer-term studies were not possible with SP600125 (data not 
shown). 
 Treatment times differed based on the experimental outcome measured. Historically, 
we have shown in our primary cultures of newly differentiated primary human adipocytes 
that t10,c12 CLA increases phosphorylation of MAPKs between 6-24 h, induces 
inflammatory gene expression and protein secretion between 12-48 h, decreases 
adipogenic gene expression from 18-72 h, and PPARγ protein from 24-48 h [9,10, 18, 19, 
32, 33]. Therefore, we chose a 12 h time point to examine JNK phosphorylation, 18 h for 
inflammatory gene expression, 24 h for cytokine/chemokine secretion, and 24 h for 
adipogenic, lipogenic, and insulin-sensitizing gene xpression. The timing of these events 
fits our hypothesis that JNK phosphorylation occurs p ior to t10,c12 CLA-mediated 
induction and secretion of inflammatory proteins, leading to the suppression of 
adipogenic/lipogenic gene and protein levels. 
 c-Jun NH2-terminal kinase-mediated activation of cJun results in induction of several 
inflammatory genes including IL-8, IL-6, and COX2, and also genes involved in cell 
death or apoptosis. For example, SP600125 or RNA interference of JNK in 3T3-L1 
adipocytes prevented free fatty acid-induced MCP-1 expression [26].  Consistent with 
these data, we showed that inhibiting JNK with the chemical inhibitor SP600125 
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prevented t10,c12 CLA-mediated inflammatory gene expr ssion and protein secretion 
(Fig. 2).  This prevention was accompanied by an increase in the expression lipogenic 
and insulin sensitizing genes and PPARγ protein levels that promote lipogenesis or 
insulin signaling (Fig. 3).  
 One possible explanation for these data is that by inhibiting JNK activity, t10,c12 
CLA was unable to decrease PPARγ activity, which drives the expression of genes that
promote glucose and fatty acid uptake and triglyceride synthesis and deposition in 
adipocytes.  Indeed, PPARγ2 activity is regulated by phosphorylation [27].  Notably, 
phosphorylation at serine residue 112 by ERK or JNK has been reported to decrease 
PPARγ activity by ubiquination and proteosome degradation [28], and by decreasing its 
ligand-dependent and ligand-independent transactivating functions [15, 29-31]. 
Consistent with this hypothesis, we have shown that10,c12 CLA increases PPARγ 
phosphorylation prior to reducing PPARγ protein levels. Furthermore, supplementation 
with Rosiglitazone, a PPARγ agonist [32], or resveratrol, an anti-inflammatory 
polyphenol [33], attenuates delipidation by t10,c12 CLA.  Thus, inhibiting t10,c12 CLA-
mediated JNK signaling may increase PPARγ activity, thereby increasing the expression 
of lipogenic and insulin-signaling genes. Consistent with this hypothesis, SP600125 
supplementation of t10,c12 CLA-treated cultures increased the expression of lipogenic 
and insulin-signaling genes compared to cultures trated with  t10,c12 CLA alone (Fig. 
3). 
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 We previously showed using the ERK inhibitor U0126 that ERK activation by 
t10,c12 CLA is one mechanism by which t10,c12 CLA suppresses lipogenic gene 
expression and insulin-stimulated glucose uptake [9]. Therefore, it is tempting to 
speculate that t10,c12 CLA antagonizes PPARγ activity via activation of MAPK like 
ERK and JNK, thereby inhibiting PPARγ target genes.  In support of this hypothesis, 
knockdown of JNK1, but not JNK2, increased basal and troglitazone-stimulated PPARγ 
reporter activity [34].  
 c-Jun NH2-terminal kinase deficiency in animals on a high-fat diet protects them 
from developing insulin resistance [20]. Similarly, mitochondrial dysfunction-induced 
insulin resistance in 3T3-L1 adipocytes is prevented by knockdown of JNK1 [35].  
Several reports show that JNK directly phosphorylates insulin receptor substrate (IRS)-1 
at serine 307, thus inactivating insulin receptor signaling. However, we did not observe 
any effects of t10,c12 CLA or SP600125 on IRS-1 ser 307 phosphorylation (data not 
shown), in spite of SP600125 blocking t10,c12 CLA induction of SOCS-3, a protein 
reported to phosphorylate ser 307 on IRS-1.  Nevertheless, t10,c12 CLA-mediated 
suppression of the mRNA levels adiponectin and GLUT4, proteins associated with 
insulin sensitivity, was completely prevented by SP600125 (Fig. 4).   
 Taken together, these data suggest that JNK may be an important target for 
preventing t10,c12-CLA mediated inflammation. Furthe  studies are needed to confirm a 
role for JNK in t10,c12 CLA-mediated insulin resistance. RNA interference studies 
targeting JNK are also needed to confirm these data.  Future research will also focus on 
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identifying upstream activators of JNK and ERK and potential mechanisms by which 
these MAPK pathways are linked to insulin resistance and suppression of lipogenesis in 
adipocytes.  
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FIGURE 4.1.  The JNK inhibitor SP600125 attenuates t10,c12 CLA-mediated 
activation of cJun and ATF3. (a)  Cultures of newly-differentiated human adipocytes 
were treated with BSA vehicle or 50 µM t10,c12 CLA for 6, 12, or 24 h. Nuclear and 
cytosolic fractions were prepared using the Nuclear Extract Kit from Active Motif 
(Carlsbad, CA) and analyzed for the determination of the protein levels of P-JNK, JNK, 
P-cJun, cJun, GAPDH, and nucleoporin. (b) Cultures were pretreated for 30 min with 5, 
20, or 80 µM SP600125 (SP) followed by a 12 h treatment with BSA vehicle or 50 µM 
t10,c12 CLA.  Subsequently, total cell lysates were harvested for the determination of the 
protein levels of P-cJun, cJun, ATF3, and GAPDH.  Data are representative of two (a) or 
three (b) independent experiments.  
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FIGURE 4.2. SP600125 attenuates t10,c12 CLA  induction of inflammatory genes. 
(a) Cultures of newly-differentiated human adipocytes were pretreated with 5, 20, or 80 
µM SP600125 (SP) for 30 min, followed by treatment wi h BSA vehicle or 50 µM 
t10,c12 CLA  for 18 h (a) or 24 h (b).  Subsequently, RNA was harvested and the mRNA 
levels of IL-8, IL-6, IL-1β, MCP-1, ATF3, and COX-2 were measured by real time qPCR 
and normalized to GAPDH endogenous control. Means (+SE; n=2-3 (a) or n=4 (b)) not 
sharing a lower case letter differ significantly (p<0.05). (b). Media were collected and 
analyzed for IL-8, IL-6, and MCP-1 levels using theBioRad Multiplex System. Data are 
representative of two (b) or three (a) independent experiments.  
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FIGURE 4.3. SP600125 blocks t10,c12 CLA suppression of lipogenic genes. Cultures 
of newly-differentiated human adipocytes were pretreated with 5, 20, or 80 µM 
SP600125 (SP) for 30 min, followed by treatment with BSA vehicle or 50 µM t10,c12 
CLA  for 24 h.  (a) RNA was harvested and the mRNA levels of PPARγ, PPARα, 
LXRα,   SREBP-1c, ACC-1, and SCD-1 were measured using real time qPCR and 
normalized to GAPDH endogenous control. Means (+SE; n=2-3) not sharing a lower case 
letter differ significantly (p<0.05). (b) Cultures were harvested for the determination of 
the protein levels of PPARγ and GAPDH. PPARγ levels were quantified by densitometry 
and normalized to the loading control, GAPDH. Densitometry values are expressed as % 
of BSA vehicle control. Data are representative of two (b) or three (a) independent 
experiments.  
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FIGURE 4.4.  SP600125 prevents t10,c12 CLA-mediated regulation of genes 
involved in insulin signaling.  Cultures of newly-differentiated human adipocytes were 
pretreated with 5, 20, or 80 µM SP600125 (SP) for 30 min, followed by treatment with 
BSA vehicle or 50 µM t10,c12 CLA  for 24 h.  Subsequently, RNA was harvested and 
the mRNA levels of SOCS-3, GLUT4, and apm1 were measured by real time qPCR and 
normalized to GAPDH endogenous control. Means (+SE; n=2-3) not sharing a lower case 
letter differ significantly (p<0.05).  
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CHAPTER V 
 
R59022 ATTENUATES TRANS-10, CIS-12 CONJUGATED LINOLEIC ACID- 
MEDIATED INFLAMMATION AND INSULIN RESISTANCE IN PRIMARY 
HUMAN ADIPOCYTES  
 
  
Abstract 
 
Diacylglycerol kinases (DGKs) convert diacylglycerol into phosphatidic acid, which has 
been reported to stimulate calcium release from the ER. Based on our published data 
showing that trans-10, cis-12 conjugated linoleic acid (t10,c12 CLA)-mediated 
intracellular calcium accumulation is linked to inflammation and insulin resistance, we 
hypothesized that chemically inhibiting DGKs with R59022 would prevent t10,c12 CLA-
mediated inflammatory signaling and insulin resistance in human adipocytes.  Consistent 
with our hypothesis, R59022 attenuated t10,c12 CLA-induced interleukin (IL)-8, IL-6, 
monocyte chemoattractant protein-1 (MCP-1), and protein secretion, and attenuated 
t10,c12 CLA-mediated suppression of peroxisome prolife ator activated receptor γ gene 
and protein levels, delipidation, insulin-stimulated glucose uptake, and glucose 
transporter 4 and adiponectin mRNA levels. DGKη was targeted for investigation based 
on our findings that 1) DGKη was highly expressed in our primary cultures of newly-
differentiated human adipocytes and induced by t10,c12 CLA-treatment, 2) t10,c12 CLA-
induced DGKη expression was dose-dependently decreased with R59022 pretreatment, 
and 3) t10,c12 CLA increased DGKη translocation to the plasma membrane compared to
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the vehicle control. Taken together, these data suggest that DGKs mediate t10,c12 CLA-
induced inflammatory signaling and insulin resistance in primary human adipocytes.  
 
Introduction 
 Overweight and obesity is a global health issue aff cting 1.6 billion individuals 
worldwide [1]. This high prevalence of overweight and obesity has resulted in an annual 
economic cost of 300 billion in the U.S. and Canada in 2009 [2]. One potential strategy 
for reducing adiposity is consumption of conjugated linoleic acid (CLA), a group of 
conjugated octadecadienoic acid isomers derived from linoleic acid, a fatty acid (FA) that 
contains 18 carbons and 2 double bonds in the cis configuration at the 9th and 12th 
carbons (i.e., cis-9, cis-12 octadecadienoic acid). CLA is found in ruminant meats and 
dairy products, as microbes in the gastrointestinal tract of ruminant animals convert 
linoleic acid into different isoforms of CLA through biohydrogenation. This process 
changes the position and configuration of the double bonds, resulting in a single bond 
between the two double bonds. The major isomers produced include cis-9, trans-11 
(c9,t11) and trans-10, cis-12 (t10,c12) octadecadienoic acid. Food sources of CLA 
contain ~80% c9,t11 CLA and 10% t10,c12 CLA, and the remaining 10% is composed of 
other isomers. CLA is also produced chemically from linoleic acid for inclusion in 
supplements and fortified foods, yielding a compositi n containing ~40% c9,t11 CLA, 
~40% t10,c12 CLA isomers, and the remaining 20% of other isomers.  
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Consuming a mixture of c9,t11 and t10,c12 CLA isomers, or t10,c12 CLA alone, 
reduces body fat mass in rodents, particularly mice, and some humans [reviewed in 3]. 
However, the isomer-specific mechanism by which CLA reduces adiposity is unclear. 
Furthermore, a number of clinical studies report potential side effects of CLA 
supplementation including increased levels of markers of inflammation (e.g., 
inflammatory cytokines, chemokines, or prostaglandins), insulin resistance, 
hyperlipidemia, and lipodystrophy [4-8]. These anti-obesity and adverse side effects of 
CLA appear to be due primarily to the t10,c12 CLA isomer. In contrast, the c9,t11 CLA 
isomer appears to have anti-inflammatory and anti-diabetic properties without reducing 
body weight [9]. 
 Several mechanisms by which t10,c12 CLA supplementation reduces body weight 
and body fat mass have been reported [reviewed in 3]. These include increasing energy 
expenditure via increasing basal metabolic rate, lipid oxidation, and thermogenesis, and 
lean body mass via increasing bone mineral density and muscle growth. Other 
mechanisms include adipocyte lipolysis, adipocyte apoptosis, and reducing glucose and 
FA uptake in adipose tissue. Our lab has extensively studied the mechanisms by which 
t10,c12 CLA promotes delipidation in adipocytes. Wehave demonstrated that activation 
of extracellular signal-regulated kinase (ERK) [10] and nuclear factor kappa B (NFκB) 
plays a role in t10,c12 CLA-mediated delipidation and insulin resistance [11]. We have 
also determined that t10,c12 CLA-mediated activation of ERK, cJun N-terminal kinase 
(JNK), NFκB, and production of reactive oxygen species (ROS) was dependent on 
accumulation of intracellular calcium levels. For example, BAPTA, a calcium chelator, 
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TMB-8, which blocks calcium release from the endoplasmic reticulum (ER), and D609, 
an inhibitor of phospholipase C (PLC), attenuated phos horylation of ERK and JNK, 
production of ROS, and induction of inflammatory genes. Additionally, we demonstrated 
that TMB-8 prevented t10,c12 CLA-mediated NFκB binding to promoters of interleukin 
(IL)-8 and cyclooxygenase (COX)-2 [12]. Moreover, this type of inflammatory signaling 
has been directly associated with antagonism of adipogenic transcription factors like 
peroxisome proliferator activated receptor (PPAR)γ. Activated NFκB [13-15] and ERK 
[16-18] induce markers of inflammation and antagonize peroxisome proliferator activated 
receptor (PPAR)γ activity, thereby causing insulin resistance. These data suggest that 
t10,c12 CLA mediates inflammatory signaling that anagonize adipogenic processes in 
adipocytes. However, the upstream signals responsible for t10,c12 CLA-mediated 
increases in intracellular calcium levels, inflammatory signaling, insulin resistance, and 
reduced triglyceride (TG) content in human adipocytes are unknown. 
 Diacylglycerol kinases (DGKs) are a family of kinases that phosphorylate 
diacylglycerol (DAG), resulting in the conversion of DAG into phosphatidic acid (PA). 
DAG and PA act as second messengers that activate an arr y of target proteins resulting 
in significant changes in cellular signaling. For example, DAG activates conventional 
protein kinase C (cPKC), Unc-13, and protein kinase D, while PA activates atypical 
PKC, phosphatidylinositol (PI)-4-phosphate 5-kinase (PIP5K), and mammalian target of 
rapamycin (mTOR), RasGAP, and Raf-1 kinase. Therefore, DGKs are critical in 
terminating DAG signaling and also initiating PA signaling. In addition to this well-
characterized function, DGKs also act as scaffolding proteins and regulate subcellular 
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signaling via endosomal and nuclear transport. To date, 10 different DGK isozymes have 
been identified. Each of the DGKs has up to three PKC-like C1 domains and a catalytic 
region. DGKs are grouped into five different types, based on their structural and 
functional features. For example, type 1 DGKs that include DGK α, β, and γ, contain 
recoverin homology domains and EF-hand motifs that serve as calcium-binding domains 
[reviewed in 19]. Thus, these DGKs are activated in part by calcium binding. Type II 
DGKs, including DGK δ, η, and κ, contain pleckstrin homology domains, sterile α motif 
(SAM) domain, and a separated catalytic region. Type III DGKs, including DGK ε, 
contain no additional functional domains different than other DGK isoforms. Type IV 
DGKs, including DGK ζ and ι, contain a nuclear localization signal, a myristola ed 
alanine-rich C kinase substrate (MARCKS) phosphorylation domain and four ankyrin 
repeats. Type V DGKS, including DGK θ, contain three C1 domains, a Gly/Pro-rich 
domain, and a PH-domain like region [reviewed in 19]. DGKs also display tissue-specific 
expression. DGKs are highly expressed in the brain, thymus, and muscle. However, DGK 
expression in adipose tissue or primary human adipocytes is poorly defined. Thus, DGKs 
are a complex family of kinases. 
 Several lines of evidence support the involvement of DGKs in t10,c12 CLA-mediated 
inflammation and insulin resistance. First, DGK-generated PA levels activate mTOR and 
S6 kinase (S6K) in HEK 293 cells [20]. Interestingly, we reported that t10,c12 CLA 
robustly increases the phosphorylation of these twopr teins in cultures of newly 
differentiated primary human adipocytes [21]. Additionally, mTOR and S6K activation 
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have been implicated in the development of insulin resistance, a side effect of CLA 
supplementation [22, 23]. Furthermore, DGK-mediated PA production has also been 
shown to increase calcium release from the ER [24]. This finding could provide a 
mechanism by which t10,c12 CLA increases intracellular calcium levels [12]. Moreover, 
DGKη has been reported to regultate MEK/ERK activation, which we have found to be 
necessary, in part, for t10,c12 CLA-mediated insulin resistance [25, 10]. For example, 
Yasuda et al. (2009) found that DGKη facilitated the transport of c-Raf to the plasma 
membrane, upstream of MEK/ERK activation in response to epidermal growth factor 
(EGF) treatment in HeLa cells. Therefore, it is tempting to speculate that t10,c12 CLA-
mediated activation of MEK/ERK may involve similar signaling mechanisms. 
Additionally, DGKα has been shown to regulate tumor necrosis factor (TNF)α-mediated 
NFκB activation [26], which we have reported to be activated by t10,c12 CLA treatment 
in adipocytes. Finally, a mixture CLA has been shown to increase expression of DGKζ 
and increase PA levels in cardiomyocytes [27]. However, this was thought to have been 
dependent on a PPAR γ-dependent mechanism. We have historically found that t10,c12 
CLA decreases PPAR γ activity and protein levels, so whether or not DGKζ plays a role 
in CLA’s effects in adipocytes is unclear. Thus, there are several interesting findings in 
the literature that suggest a role for DGKs in t10,c 2 CLA-mediated signaling in primary 
human adipocytes.   
 Based on the close similarity between pathways activated by DGK and t10,c12 CLA, 
we hypothesized that DGKs play an important role in t10,c12 CLA-mediated 
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inflammation, insulin resistance, and delipidation. To test this hypothesis, we employed 
the chemical DGK inhibitor, R59022. By using this inhibitor, we demonstrated that 
DGKs are involved in the regulation of t10,c12 CLA-induced inflammatory signaling, 
insulin resistance, and delipidation in newly differentiated primary human adipocytes.  
Therefore, DGKs may be an important target for preventing 10,12 CLA-mediated 
inflammation and insulin resistance.                                                            
 
Materials and Methods 
Materials   
 All cell culture ware were purchased from Fisher Scientific (Norcross, GA). 
Lightning Chemiluminescence Substrate was purchased from Perkin Elmer Life Science 
(Boston, MA).  Immunoblotting buffers and precast gels were purchased from Invitrogen 
(Carlsbad, CA). Polyclonal antibodies for anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and monoclonal antibody for anti-PPARγ were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA).  Polyclona  antibody for DGKη was 
purchased from Abcam (Cambridge, MA). Anti-total and anti-phospho (P) ERK, JNK, 
and P-cJun antibodies were purchased from Cell Signaling Technologies (Beverly, MA). 
Hyclone fetal bovine serum was purchased from Fisher Scientific. Isomers of CLA 
(+98% pure) were purchased from Matreya (Pleasant Gp, PA). Fluo-3 acetyloxymethyl 
ester (Fluo-3 AM), pluronic F-127, and probenecid were purchased from Invitrogen by 
Life Technologies (Carlsbad, CA). Thapsigargin and ionomycin were purchased from 
 108 
Calbiochem-EMD Biosciences, Inc. (La Jolla, CA). The cell permeable DGK inhibitor 
R59022 (6-{2-{4-[(4-fluorophenyl)phenylmethylene]-1-piperidinyl}ethyl}-7-methyl-5H-
thiazolo-(3,2-a)pyrimidin-5-one) was purchased from EMD Chemicals (Gibbstown, NJ). 
This inhibitor functions by inhibiting DAG phosphorylation which is more specific to the 
Type 1, calcium-sensitive DGKs, but also has less specificity than another DGK 
inhibitor, R59949 (3-{2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl}-2,3-
dihydro-2-thioxo 4(1H)quinazolinone) [28]. Because we were unaware of the specific 
DGKs isoforms that may play a role in t10,c12 CLA-mediated signaling, the less specific 
inhibitor R59022 was used in this study. All other r agents and chemicals were purchased 
from Sigma Chemical Co. (St. Louis, MO) unless otherwise stated. 
 
Culturing of human primary adipocytes   
 Abdominal white adipose tissue was obtained with consent from the Institutional 
Review Boards at the University of North Carolina at Greensboro and the Moses Cone 
Memorial Hospital, during elective abdominoplasty of non-diabetic Caucasian and 
African American females between the ages of 20-50 years old with a body mass index ≤ 
32.0. These selection criteria allow for reduced variation in gender, age, and obesity 
status. Tissue was digested using collagenase; stromal vascular cells were isolated as 
previously described [10].  Stromal vascular cells were differentiated with adipocyte 
media (AM-1) containing 1 µM rosiglitazone and 250 µM 1-methyl-3-isobutylxanthine 
for 3 d, which yielded cultures containing ~30-50% adipocytes. On days 7-14, cells were 
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pretreated with 0.1, 1, 3, 10, or 30 µM R59022 dissolved in DMSO for 30 min, and 
subsequently treated with 50 -150 µM t10,c12 CLA or bovine serum albumin (BSA) 
vehicle control for 5 min - 48 h depending on the experimental outcome measured. All 
cultures were normalized to contain the same amount f BSA and DMSO vehicles. Each 
independent experiment was repeated at least twice using a mixture of cells from three 
subjects, unless otherwise indicated.  
 
Fatty acid preparation 
 t10,c12 and c9,t11 CLA was delivered as a free acid complexed to 7.5% fatty acid-
free bovine serum albumin (BSA) at a 4:1 molar ratio s previously described [10]. For 
measuring [Ca2+] i levels, t10,c12 CLA dissolved in a 0.1M KOH solution was used.  
 
TG content 
 TG levels were determined with a modified commercially-available TG assay as 
previously described [29]. 
 
3H-2-deoxyglucose uptake 
Cultures of newly-differentiated human adipocytes were supplemented with low-
glucose DMEM on day 10. The following day, cultures were pretreated with 0.1, 1, or 10 
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µM R59022 for 30 minutes and subsequently treated with BSA vehicle or 50 µM t10,c12 
CLA for 48 h. Cultures were stimulated for 10 min with 100 nM insulin and treated with 
4 nmol 3H-2-deoxyglucose for 90 min and the amount of 3H-2-deoxyglucose was 
measured via scintillation counting as described previously [29]. 
 
14C-oleic acid uptake 
Cultures of newly-differentiated human adipocytes were supplemented with low-
glucose DMEM on day 10. The following day, cultures were pretreated with 0.1, 1, or 10 
µM R59022 for 30 min and subsequently treated with BSA vehicle or 50 µM t10,c12 
CLA for 48 h. Cultures were treated with 12.5 nM 14C-oleic acid (0.2 µCi; specific 
activity = 40-60 mCi/mmol) for 120 min and the amount of radiolabled oleic acid was 
measured via scintillation counting as described previously [29]. 
 
Immunoblotting   
 Immunoblotting using 20 µg of protein per lane was conducted using 4-12% NuPage 
precasted gels as previously described [10]. Briefly, PVDF membranes were blocked 
with 5% milk in TBST for 1 h and washed 3 x in TBST for 5 min. Blots were incubated 
overnight at 4°C with primary antibodies targeting DGKη, P-ERK, P-JNK, P-cJun, and 
total cJun at a dilution of 1:1000, and subsequently incubated in the respective 
horseradish peroxidase-conjugated secondary antibody at a dilution of 1:5000 at room 
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temperature for 1 h. Primary and secondary antibodies targeting GAPDH were used at a 
1:5000 dilution. Primary and secondary antibodies targeting PPARγ were used at 
dilutions 1:200 and 1:2000, respectively. After washing, blots were treated with 
chemiluminescence reagent for 1 min and film was exposed using a SRX-101A Konica 
Minolta film developer. Densitometry was performed using a Kodak Image Station 440 
CF by Perkin Elmer and Kodak Molecular Imaging Software Version 4.0.   
 
RNA isolation and PCR   
 Total RNA was isolated from the cultures using Tri Reagent purchased from 
Molecular Research Center (Cincinnati, OH), according to manufacturer’s protocol.  For 
quantitative real time PCR, 1.0 ug total RNA was converted into first strand cDNA using 
Applied Biosystems High-Capacity cDNA Archive Kit (Foster City, CA).  Real time 
PCR was performed in an Applied Biosystems 7500 FAST Real Time PCR System using 
Taqman Gene Expression Assays.  To account for possible variation in cDNA input or 
the presence of PCR inhibitors, the endogenous referenc  gene GAPDH was 
simultaneously quantified for each sample, and these data normalized accordingly. The 
Relative Standard Curve Method using seven, two-fold dilutions ranging from 100 – 1.56 
ng RNA was used to check primer efficiency and linearity of each transcript according to 
Applied Biosystem’s Guide to Performing Relative Quantification of Gene Expression 
Using Real-Time Quantitative PCR.  
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Secretion of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein (MCP)-
1  
 The concentrations of IL-6, IL-8, and MCP-1 were dtermined using the BioPlex® 
Suspension Array System from Bio-Rad (Hercules, CA) following the manufacturer’s 
protocol.  Briefly, media was collected from cultures that were pretreated with 30 µM 
R59022 for 30 min, and subsequently treated with 50 µM t10,c12 CLA or BSA for 24 h. 
This time point was based on previous time course studies showing that the maximum 
level of cytokine secretion occurred after 24 h of t10,c12 CLA treatment [11]. The media 
was centrifuged at 13,200 x g for 10 min at 4°C to clear the samples of cellular debris. 
Samples and standards were run in duplicate. Based on the manufacturer’s report ‘Bio-
Plex Pro Human Cytokine, Chemokine, and Growth Factor Assays - Bulletin 5828,’ the 
intra-assay % CVs for IL-6, IL-8, and MCP-1 are 7, 9, and 9%, respectively. The inter-
assay % CVs are 11, 4, and 7%, respectively.  
 
Measuring [Ca2+] i levels 
 [Ca2+] i levels were determined using the calcium sensitive fluorescent dye Fluo-3 
AM. Briefly, cells were preloaded with 5 µM Fluo-3 AM and an anionic detergent, 10% 
Pluronic F-127, at 37°C for 30 min in the dark. Next, cells were washed with HBSS 
containing CaCl2 and probenecid, which prevents Fluo-3 AM leakage from cells. Cells 
were pretreated with R59022 or DMSO vehicle control for 10 min. Subsequently, 
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baseline fluorescence was measured using a Synergy Multidetection Microplate Reader 
(BioTek Inc., Winooski, VT) for 1 min at 10 s intervals. Cells were then treated with 5 
µM thapsigargin (positive control), ionomycin (positive control), or 150 µM t10,c12 CLA 
and fluorescence was monitored at 20 s intervals for 7 min. Excitation wavelength was 
485 nm, and fluorescence was collected at 528 nm. Changes in the ratio of calcium-
dependent fluorescence to prestimulus background fluorescence (F/F0) were plotted over 
time. For simplicity, single representative experiments are shown. 
 
Plasma membrane (PM) isolation and DGKη levels 
 Cultures were treated with 20% serum, 100 ng/ml EGF, 50 uM t10,c12 CLA, or BSA 
vehicle control for 5 or 15 min. Cells were washed 2 x with 5 ml ice-cold HBSS and 
harvested in 300 ul TES buffer (20 mM Tris-HCl, 225 mM sucrose, 1 mM EDTA, pH 
7.4) containing protease inhibitor at 20°C. Lysate (600 ul) from 2-100 mm culture dishes 
were homogenized in a 2 ml pre-chilled potter-elvehjem homogenizer and sheared using 
15 strokes. The lysate was centrifuged at 16,000 x g for 20 min at 4°C. The supernatant 
or cytosolic fraction was removed and re-spun to remove excess lipid, and the 
supernatant was stored at -80°C. The remaining pellet was resuspended in 500 ul TES 
buffer and centrifuged at 16,000 x g for 20 min at 4°C. The supernatant was removed and 
discarded. The pellet was resuspended in 500 ul TES buffer and re-homogenized again 
using 15 strokes with a 2 ml potter-elvehjem homogenizer. The homogenate was layered 
onto 4 ml of 1.2 M sucrose cushion in a seal-top centrifuge tube. The tube was filled 
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completely with TES buffer and sealed. The samples w re centrifuged at 100,000 x g for 
20 min at 4°C. The interphase or PM fraction was removed and re-spun at 100,000 x g 
for 30 min at 4°C. The pellet was re-suspended in 50 ul RIPA lysis buffer containing 
protease inhibitor. Immunoblotting was carried out as described previously.   
 
Statistical analyses   
 Data are expressed as the means ± S.E. Data were analyzed using one-way analysis of 
variance followed by Student’s t tests for each pair for multiple comparisons.  Differences 
were considered significant if p < 0.05.  All analyses were performed using JMP IN, 
Version 9 Software (SAS Institute, Cary, NC). 
 
Results 
 It has been previously reported that DGKs increase [Ca2+] i levels via PA-mediated 
secretion from the endoplasmic reticulum (ER) [24]. We have found that 10,12 CLA-
mediated inflammatory signaling is dependent on increased [Ca2+] i [12]. Therefore, we 
hypothesized that DGKs play a role in 10,12 CLA-mediated inflammation, insulin 
resistance, and delipidation.  
First, we sought to determine the extent to which DGKs played a significant role in 
the metabolic consequences of t10,c12 CLA treatment such as reduced lipid content and 
insulin sensitivity. In order to determine if DGKs play a role in t10,c12 CLA-mediated 
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delipidation, TG levels were measured in cultures pretreated with 3, 10, or 30 µM of the 
DGK inhibitor R59022 for 30 min and subsequently trea ed with 10,12 CLA for 24 h.  
The t10,c12 CLA-mediated reduction in TG was attenuated with 30 µM R59022 (Fig 
5.1A). Previously, we have demonstrated that t10,c12 CLA reduces 14C-labled oleic acid 
uptake and insulin-stimulated 3H-deoxy-2-glucose uptake [10]. Therefore, the 
involvement of DGKs in t10,c12 CLA-mediated suppression of FA uptake and insulin-
stimulated glucose uptake was determined. The suppression of FA uptake was dose-
dependently attenuated with R59022 (Fig 5.1B). t10,c12 CLA-mediated suppression of 
insulin-stimulated glucose uptake was attenuated with 10 µM R59022 (Fig 5.1C). 
Due to the role of PPARγ in promoting FA uptake, we hypothesized that R59022 
would also prevent CLA’s reduction in PPARγ protein levels. Consistent with our 
hypothesis, 30 µM R59022 attenuated t10,c12 CLA-mediated reduction in PPARγ 
protein levels (Fig 5.2A). Consistently, R59022 pretreatment partially prevented t10,c12 
CLA-mediated suppression of adipogenic and lipogenic genes including PPARγ, fatty 
acid binding protein (aP2), insulin-dependent glucose transporter (GLUT4), and acetyl 
CoA carboxylase (ACC)-1 (Fig 5.2B).  These data suggest that DGKs are involved in 
CLA-mediated delipidation and insulin resistance.  
We previously demonstrated that t10,c12 CLA-induced inflammation leads to a 
suppression of insulin signaling and sensitivity [10-12].   In order to demonstrate the 
involvement of DGKs in 10,12 CLA-mediated inflammatory signaling,  inflammatory 
gene expression and cytokine/chemokine release werem asured in cultures pretreated 
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with increasing doses of R59022 and subsequently treated with BSA vehicle control or 
50 µM 10,12 CLA for 18 h.  R59022 significantly attenuated 10,12 CLA-induced IL-8, 
IL-6, cyclooxygenase (COX)-2, and MCP-1 gene expression (Fig 5.3A) and protein 
secretion (Fig 5.3B). These data suggest the DGKs are involved in t10,c12 CLA-
mediated inflammatory signaling in primary cultures of newly differentiated human 
adipocytes.  
We have previously shown that t10,c12 CLA-induced inflammation is dependent on 
MAPK activation [10] and [Ca2+] i accumulation [12]. Therefore, we examined the roleof 
DGKs in t10,c12 CLA-mediated MAPK (i.e., ERK and JNK) and activator protein (AP)-
1 (i.e., cJun)  activation, due to their role in upregulating inflammatory gene expression. 
Indeed, 30 µM R59022 attenuated t10,c12 CLA-mediated ERK, JNK, and c-Jun 
phosphorylation (Fig 5.4A). These data suggest that DGKs are involved in CLA-
mediated MAPK and c-Jun phosphorylation. Due to the involvement of intracellular 
calcium in 10,12 CLA-mediated inflammatory signaling, the role of DGKs in elevating 
[Ca2+] i levels by 10,12 CLA was determined. Cultures were pr treated with increasing 
doses of R59022 for 10 min, and subsequently treated with 10,12 CLA after which 
[Ca2+] i were measured using the fluorescent calcium indicator Fluo3-AM. As reported 
previously, 10,12 CLA increased [Ca2+] i within 1 min. R59022 decreased [Ca
2+] i elevated 
by 10,12 CLA (Fig 5.4B). In order to better understand how R59022 functios to 
decrease [Ca2+] i, calcium levels were measured in cultures treated with ionomycin, which 
causes calcium influx from outside the cell, and thapsigargin, which inhibits calcium-
ATPases on the ER causing calcium release from the ER, in the presence or absence of 
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R59022. Interestingly, R59022 decreased both ionomycin and thapsigargin-mediated 
calcium accumulation. However, R59022 completely blocked ionomycin-mediated 
calcium and only partially attenuated thapsigargin-mediated calcium accumulation (Fig 
5.4C). These data suggest that DGKs may be involved in t10,c12 CLA-mediated increase 
in [Ca2+] i from both intra- and extracellular stores.   
In order to determine the DGK isoform responsible for these effects, we analyzed 
basal gene expression of several DGK isoforms including DGKα, δ, γ, η, and ζ. These 
isoforms were chosen based on microarray analyses of all DGK isoforms (data not 
shown). DGKα was the most highly expressed isoform (Fig 5.5A). DGKδ and DGKη 
were expressed at similar levels, whereas DGKζ and DGKγ were the least abundant 
isoforms (Fig 5.5A). In order to assess the effect of t10,c12 CLA on DGK expression, 
cultures were treated with 50 µM t10,c12 CLA from 3 to 24 h. DGKη and DGKδ were 
modestly induced by t10,c12 CLA treatment after 12-24 h and DGKγ was modestly 
induced after 24 h of treatment (Fig 5.5B). There was no effect of t10,c12 CLA on 
DGKα or DGKζ expression at any time point (data not shown). Thepotential self-
regulation of DGK expression was determined by analyzing cultures pretreated with 
R59022 and subsequently treated with t10,c12 CLA for 18 h. R59022 significantly 
decreased t10,c12 CLA-induced DGKη and DGKδ, but not DGKγ, mRNA levels (Fig 
5.5C). Based on these results, DGKη and DGK δ were targeted for further study.  
The activation of DGKη and DGKδ by t10,c12 CLA was investigated by analyzing 
their translocation from the cytosol to the PM following t10,c12 CLA treatment using 
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ultracentrifugation of cell extracts on a sucrose gradient to isolate the PM. Subsequently, 
PM and cytosolic fractions were immunoblotted for several DGK isoforms. t10,c12 CLA 
and the positive control epidermal growth factor (EGF) increased DGKη (n=2) within 5 
min of treatment, but not DGKδ (data not shown), translocation compared to BSA 
control (Fig 5.6). However, subsequent independent experiments (n=5) did not show any 
effect of CLA or EGF on DGKη translocation at 5 min, raising doubt about our 
hypothesis that t10,c12 CLA directly increases DGKη activity.  Of the five subsequent 
reps, EGF and CLA increased DGKη translocation at 15 min (n=1), so there was also 
inconsistency in the treatment effects across experiments. Based on work by Yasuda and 
colleagues showing that DGKη facilitated c-Raf and b-Raf translocation to the PM, c-Raf 
and b-Raf levels were also measured in the PM [25]. EGF, but not t10,c12 CLA, 
consistently increased c-Raf (n=4) and b-Raf (n=3) translocation to the PM. Taken 
together, these data suggest that the hypothesized increase in DGKη activity by t10c12 
CLA does not occur by a mechanism similar to EGF. 
 
Discussion 
 Consistent with our hypothesis, R59022 attenuated t10,c12-mediated suppression of 
TG levels, radiolabeled oleic acid uptake, insulin-stimulated glucose uptake, PPARγ 
protein levels and target gene expression. Additionally, R59022 suppressed t10,c12 CLA-
induced inflammatory gene and protein secretion, and MAPK and cJun phosphorylation, 
as well as [Ca2+] i. Taken together, these data suggest that DGKs plays role in t10,c12 
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CLA-mediated induction of inflammation and insulin resistance in cultures of human 
adipocytes.  However, t10,c12 CLA did not consistently i crease DGKη translocation to 
the PM, casting doubt on the extent to which t10,c12 CLA directly increases the activity 
of this isoform, and the specificity of R59022.  DGK silencing experiments are needed to 
corroborate the DGK chemical inhibitor data.  
 Further research is needed to confirm a role for DGKs in t10,c12 CLA-mediated 
inflammation, insulin resistance, and delipidation. As with most chemical inhibitors, 
there have been issues reported regarding the efficacy and specificity of R59022 [28]. 
Because we were unsure which DGK isoform might be involved in inflammatory 
signaling pathways in adipocytes, we decided to use R59022, rather than the more 
specific Type 1 DGK inhibitor, R59949. In preliminary experiments using R59949, we 
found it had little effect on reducing inflammatory gene expression and did not 
significantly attenuate t10,c12 CLA-mediated suppression of insulin-stimulated glucose 
uptake (data not shown). These findings suggest that Type 1 DGKs may not play a role in 
t10,c12 CLA signaling. However, DGKα displayed the highest level of expression in our 
primary cultures of newly differentiated human adipocytes (Fig 5.5). Based on data 
presented here, we expect that DGKη and DGKα may be important targets to investigate 
in the future. Therefore, gene silencing studies using iRNA targeting DGKη and α will 
be conducted to determine their role in inflammation and insulin resistance mediated by 
t10,c12 CLA in primary human adipocytes. 
 A common mechanism by which FA increase calcium levels is through activation of 
G-protein coupled receptors (GPCRs), such as GPR40. GPR40, coupled to the G-protein 
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subunit Gαq/11, activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 
4,5-bisphosphate (PIP2) into DAG and inositol phosphates (InsPs). InsPs activate 
receptors on the ER, triggering calcium mobilization [reviewed in 30]. Intriguingly, it 
was recently reported by Schmidt and colleagues that CLA increases [Ca2+] i and 
stimulates insulin release from INS-1E pancreatic cells via activation of the cell surface 
receptor, FFA1/GPR40 [31]. An alternative mechanism to FA-mediated calcium 
accumulation has been proposed by Camina and colleagues, whereby PC-specific PLC, 
activated by a pertussis toxin (PTX)-sensitive g protein, generates choline and DAG, 
which is converted into PA by DGKs. PA subsequently triggers calcium mobilization 
from inositiol-3-phosphate–independent calcium pools [24, 32–34]. Consistent with these 
findings, we reported recently that D609, a phosphatidylcholine (PC)-specific PLC (PC-
PLC) inhibitor, prevents t10,c12 CLA-mediated calcium accumulation, ROS production, 
and inflammatory gene expression (i.e., IL-8, ATF3, and COX-2) [12]. Notably, we have 
previously shown that PTX attenuates t10,c12 CLA-mediat d MEK/ERK 
phosphorylation and suppression of 14C-oleic acid uptake and insulin-stimulated 3H-2-
deoxyglucose uptake, suggesting that t10,c12 may activate inflammatory signaling 
pathways via activation of a GPCR. Moreover, in the pr sent study, we found that the 
DGK inhibitor, R59022, decreased t10,c12 CLA-mediated [Ca2+] i accumulation (Fig 
5.4). Elevated [Ca2+] i activates calcium-sensitive proteins like calmodulin (CaM) which 
activates a number of kinases including CaMKII, which has been shown to inhibit 
differentiation upon PGF2α treatment [35]. Interestingly, we have shown that KN-62, a 
CaMKII inhibitor attenuated t10,c12 CLA-mediated ERK and JNK phosphorylation, 
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ROS production, induction of inflammatory genes, PGF2α secretion, and suppression of 
PPARγ protein levels and insulin-stimulated glucose uptake [12]. We found that R59022 
also decreased CaMKIIβ gene expression (data not shown), thus providing aother 
mechanism by which DGKs mediate 10,12 CLA-induced inflammation. Collectively, 
these findings support mechanisms by which t10,c12 CLA may trigger intracellular 
calcium accumulation and subsequent activation of iflammatory pathways.  
 DGK-generated PA has also been shown to activate other kinases such as mTOR and 
S6K. Both of these proteins have been implicated in regulating insulin resistance [22-23]. 
For example, it was shown in 3T3-L1 adipocytes thatexpression of a dominant negative 
mutant of S6K blunted the suppression of insulin-stmulated glucose uptake mediated by 
tumor necrosis factor (TNF)α. The insulin-resistant effects of S6K were found to be due 
to phosphorylation of IRS-1 on Ser-265/270 [22]. It was also found that insulin-resistant 
ob/ob mice [22] or mice fed a high-fat high-sucrose di t [23] had increased levels of 
mTOR and S6K activation compared to lean controls [22-23].  Interestingly, we have 
previously shown that t10,c12 CLA robustly increases the phosphorylation of mTOR and 
S6K in primary human adipocytes [21].  Furthermore, it was shown that inhibitors of 
GPCRs (PTX), mTOR (rapamycin), phosphatidylinositol 3-kinase (LY-294002), and 
protein kinase C (calphostin C) blocked the phosphorylation of mTOR and S6K [21]. The 
activation of these proteins could provide a mechanism by which DGKs mediate t10,c12 
CLA-induced insulin resistance in human adipocytes. However, future studies are needed 
to test this hypothesis. 
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 Treatment times in this study differed based on the experimental outcome measured. 
Historically, we have shown in our primary cultures of newly differentiated primary 
human adipocytes that t10,c12 CLA increases calcium accumulation from 1-7 min, 
phosphorylation of MAPKs between 6-24 h, induces inflammatory gene expression and 
protein secretion between 12-48 h, decreases adipogenic ene expression from 18-72 h, 
PPARγ protein and TG levels from 24-48 h, and FA and insuli -stimulated glucose 
uptake after 48 h [10, 11, 12, 36, 37, 38]. Therefore, we chose a 12 h time point to 
examine MAPK phosphorylation, 18 h for inflammatory gene expression, 24 h for 
cytokine/chemokine secretion, and 24 h for adipogenic, lipogenic, and insulin-sensitizing 
gene expression, and 24-48 h for measuring levels of TG and glucose and fatty acid 
uptake. The timing of these events fits our hypothesis that DGK activation occurs prior to 
t10,c12 CLA-mediated induction and secretion of inflammatory proteins, leading to the 
suppression of adipogenic/lipogenic gene and protein levels. 
  Based on the data reported herein and reports from the literature, we propose the 
working model presented in Fig 5.7, whereby t10,c12 CLA activates a GPCR linked to 
PLC, that generates IP3 and DAG. DGKs convert DAG into PA, and together with IP3, 
PA stimulates calcium secretion from the ER. Elevatd calcium levels activate calcium-
sensitive kinases such as CAMKII, which promotes ROS production and MAPK 
activation, leading to the induction of inflammatory genes by NFκB and AP-1. Secreted 
inflammatory proteins, such as IL-6 and TNFα, exacerbate inflammatory signaling in 
adipocytes in an autocrine and paracrine fashion. Together with direct inhibition by 
NFκB or AP-1, these inflammatory signals antagonize PPARγ, leading to decreased 
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glucose and FA uptake, resulting in delipidation and insulin resistance in adipocytes (Fig 
5.7).  In summary, this study suggests that DGKs may be an important target for 
preventing t10,c12 CLA-mediated inflammation and insulin resistance. 
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FIGURE 5.1. R59022 (R5) attenuates trans-10, cis-12 (t10,c12) CLA-mediated 
suppression of triglyceride (TG) levels, 14C-oleic acid uptake, and insulin-stimulated 
3H-2-deoxy-glucose uptake. A) Cultures of newly-differentiated human adipocytes were 
pretreated with 3, 10, or 30 µM R5 and subsequently treated with BSA vehicle or 50 µM 
t10,c12 CLA (CLA) for 24 h on d 12. Cells were harvested and TG content was 
determined using a colorimetric assay. B-C) Cultures of newly-differentiated human 
adipocytes were supplemented with low-glucose DMEM on day 10. The following day, 
cultures were pretreated with 0.1, 1, or 10 µM R5 for 30 minutes and subsequently 
treated with BSA vehicle or 50 µM t10,c12 CLA for 48 h. Cultures were stimulated for
10 min with 100 nM insulin and treated with 3H-2-deoxyglucose  and 14C-oleic acid for 
90 min or 120 min, respectively. Data are representative of two (B) or three (A,C) 
independent experiments. Means ± SEM (n = 4) not sharing a common superscript differ 
significantly (p < 0.05). 
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FIGURE 5.2. R59022 (R5) attenuates trans-10, cis-12 (t10,c12) CLA-mediated 
suppression of PPARγ protein levels and adipogenic/lipogenic gene expression. A-B) 
Cultures of newly-differentiated human adipocytes were pretreated with 3, 10, or 30 µM 
R5 and subsequently treated with BSA vehicle or 50 µM t10,c12 CLA (CLA) for 24 h 
(A) or 18 h (B) on d 8-10. A) Cells were harvested for protein and immunoblotted for 
PPARγ and GAPDH control. B) Cells were harvested for RNA and mRNA levels were 
measured via RT-qPCR. Data are representative of two (B) or three (A,C) independent 
experiments. Means ± SEM (n = 3-4) not sharing a comm n superscript differ 
significantly (p < 0.05). 
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FIGURE 5.3. R59022 (R5) attenuates trans-10, cis-12 (t10,c12) CLA-induced 
inflammatory gene expression and protein secretion. A-B) Cultures of newly-
differentiated human adipocytes were pretreated with 3, 10, or 30 µM R5 and 
subsequently treated with BSA vehicle or 50 µM t10,c12 CLA (CLA) for 18 h (A) or 24 
h (B)  on d 7-10. A) Cells were harvested for RNA and mRNA levels were measured via 
RT-qPCR. B) Media was collected and IL-8, IL-6, and MCP1 were masured via 
BioPlex® Suspension Array System from Bio-Rad. Data are representative of three 
independent experiments. Means ± SEM (n = 3-4) not sharing a common superscript 
differ significantly (p < 0.05). 
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FIGURE 5.4. R59022 (R5) attenuates trans-10, cis-12 (t10,c12) CLA-mediated 
MAPK and cJun phosphorylation and intracellular [Ca2+] i accumulation. A) 
Cultures of newly-differentiated human adipocytes were pretreated with 3, 10, or 30 µM 
R5 and subsequently treated with BSA vehicle or 50 µM t10,c12 CLA (CLA) for 24 h on 
d 8-10. B-C) Cultures of newly differentiated human adipocytes were preloaded with 5 
µM Fluo-3 AM. Cultures were injected with vehicle (-), 5 µM thapsigargin (Tg; filled 
square), ionomycin (iono; filled diamond) 150 µM CLA (filled circle), or pretreated with 
R5 for 10 min and injected with 150 uM CLA (open circle), 5 µM Tg (open square), or 
ionomycin (open diamond) for 7 min at 20 s intervals. Baseline fluorescence was 
measured prior to treatment injection for 1 min at 10 s intervals. Data are representative 
of three independent experiments. B-C) Emitted fluorescence intensities were collected 
over time using a multidetection microplate reader. Excitation wavelength was 485 nm, 
and fluorescence was collected at 528 nm. Data are expressed as a ratio to baseline 
fluorescence (F0). Means ± SEM (n = 3-4) not sharing a common superscript differ 
significantly (p < 0.05).  
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FIGURE 5.5. R59022 (R5) attenuates trans-10, cis-12 (t10,c12) CLA-induced DGK 
gene expression. A) Basal expression of DGK α, η, δ, ζ, and γ was measured in cultures 
of newly-differentiated human adipocytes on d8. B) Cultures were treated with BSA 
vehicle or 50 µM t10,c12 CLA (CLA) for 3-24 h, or  C) pretreated with 3, 10, or 30 µM 
R5 and subsequently treated with BSA vehicle or 50 µM t10,c12 CLA (CLA) for 18 h 
and mRNA levels were measured via RT-qPCR. Data are representative of two (A-B) to 
three (C) independent experiments. Means ± SEM (n = 2-3) not sharing a common 
superscript differ significantly (p < 0.05). 
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FIGURE 5.6. Epidermal growth factor (EGF) and trans-10, cis-12 (t10,c12) CLA 
treatment triggered DGKη translocation to the plasma membrane (PM). Cultures of 
newly-differentiated human adipocytes were treated with BSA (B) vehicle control, 20% 
serum (S), 100 ng/ml EGF (E), or 50 µM t10,c12 CLA (C) for 5 or 15 min. Total cell 
extracts were harvested and cytosolic and plasma membrane fractions were isolated by 
differential centrifugation. Each fraction was immunoblotted for DGKη, c-Raf, b-Raf, 
and caveolin-1. Data are representative of two of seven independent experiments. 
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FIGURE 5.7. Working Model. t10,c12 CLA activates a g-protein coupled receptor 
linked to PLC. PLC cleaves phosphatidylinositol-bisphosphate (PIP2) or 
phosphatidylcholine (PC) into DAG and IP3 or choline, respectively.  IP3 activates the 
IP3 receptor on the ER, and PA produced by DGK, stimulates Ca2+ release from the ER. 
Intracellular Ca2+ activates calcium-sensitive kinases like calmodulin kinase (CAMK) II 
leading to ROS production and MAPK activation. Activa ed AP-1 or NFkB suppress 
PPARγ activity leading to reduced glucose and FA uptake, thus promoting delipidation 
and insulin resistance in adipocytes.  
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CHAPTER VI 
 
EPILOGUE 
 
 
The prevalence of obesity has risen dramatically over the past 30 years in the U.S. 
and is becoming a global health issue. Although combating obesity would be best 
achieved by diet and exercise, supplemental agents have become increasingly popular. 
One such agent is conjugated linoleic acid (CLA). Supplementation of CLA has been 
shown to reduce body weight and fat mass in several animal models and in some humans. 
However, the safety and efficacy of CLA in reducing body weight and fat mass is 
controversial, as it has been reported to promote inflammation and insulin resistance in 
animals and humans. Therefore, it is imperative to better understand CLA’s mechanism 
of action and adverse side effects in white adipose tissue (WAT). Furthermore, the cell 
type in WAT that is responsible for mediating inflammatory signaling in response CLA is 
unclear. Thus, it is equally important to identify the cell type initiating CLA’s adverse 
side effects.  
Results from our lab suggest that t10,c12 CLA-mediat  delipidation is linked to 
inflammatory signaling and insulin resistance. For example, we have demonstrated that 
t10,c12 CLA induces inflammation and insulin resistance via elevation of intracellular 
calcium levels, activation of extracellular signal-regulated kinase (ERK), nuclear factor 
kappa B (NFκB), and activator protein (AP)-1, which upregulate inflammatory proteins 
such as tumor necrosis factor (TNF)-α and interleukin (IL)-6. Secretion of these
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cytokines and direct inhibition by NFκB attenuates the activation of transcription factors, 
such as peroxisome proliferator-activated receptor (PPAR)γ and sterol regulated enhancer 
binding protein (SREBP)-1c, that promote glucose and fatty acid uptake, fatty acid 
synthesis, and TG storage in adipocytes. However, th  cell type in our cultures of newly 
differentiated primary human adipocytes responsible for initiating inflammatory signaling 
is unknown. Furthermore, the upstream signaling mechanisms activated by 10,12 CLA 
that trigger intracellular calcium accumulation, inflammatory protein activation (i.e., 
ERK and NFκB), and result in insulin resistance and delipidation are unknown. 
Therefore, I investigated 1) the cell type that is re ponsible for initiating the inflammatory 
response to CLA and 2) the upstream mechanisms involved, where I specifically 
examined the role of cJun N-terminal kinase (JNK) and diacylglycerol kinase (DGK) in 
CLA-mediated inflammation, insulin resistance, and delipidation.  
Based on the results from these studies, I propose that adipocytes are essential for 
the inflammatory response to CLA. Additionally, treating primary cultures of newly 
differentiated human adipocytes with 10,12 CLA increases the phosphorylation of 
mitogen-activated protein kinases (MAPK)s including ERK 1/2, JNK, and p38, and the 
activation of the transcription factor AP-1 [i.e., c-Jun and activating transcription factor 
(ATF)3], which leads to the production of inflammatory adipocytokines and 
prostaglandins (PG)s through upregulating inflammatory genes [i.e., cyclooxygenase 
(COX)-2, IL-6, IL-1β, IL-8, monocyte chemoattractant protein (MCP)-1, and ATF3]. 
These inflammatory signals subsequently activate preadipocytes, leading to inflammatory 
cytokine secretion from preadipocytes, thus continuing the inflammatory cycle. It was 
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also found using chemical inhibitors targeting JNK and DGK, that these kinases are 
involved in t10,c12 CLA-mediated inflammatory signali g and/or insulin resistance. 
Based on these findings, I have developed the following research questions: 1) Which 
DGK isoform is responsible for mediating t10,c12 CLA’s effects and will knocking down 
this isoform prevent t10,c12 CLA-mediated inflammatory signaling and insulin 
resistance?, 2) What role does phospholipase C (PLC) play in t10,c12 CLA-mediated 
inflammation?, and 3) Is t10,c12 CLA-mediated inflammatory signaling dependent on G-
protein coupled receptor (GPCR) activation?  
Q1. Which DGK isoform is responsible for mediating t10,c12 CLA’s effects and 
will knocking down the gene prevent t10,c12 CLA-mediat  inflammatory signaling? 
In order to fully address the role of DGKs in t10,c12 CLA-mediated inflammation 
and insulin resistance, several experiments are needed. First, it is still unclear which 
isoform is activated by t10,c12 CLA. Although we have preliminary data showing that 
t10,c12 CLA activates DGKη translocation to the plasma membrane (PM) (n=2), this 
effect should be confirmed with other activity assays, such as immunostaining DGKs to 
detect translocation. Alternatively, phosphatidic acid (PA) production could be measured, 
which is an indirect but common method of determining DGK activity. In addition, it is 
also important to identify the specific DGK isoforms involved in t10,c12 CLA-mediated 
signaling. It was attempted to evaluate the activity of five DGK isoforms (i.e., DGKη, δ, 
γ, α, ζ) by investigating their translocation to the PM. However, either no effect was 
evident with these DGK isoforms or the antibody was poor. Therefore, it will be 
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important in the future to obtain better antibodies for a more accurate evaluation of DGK 
activity or use different methods. Lastly, data generated thus far implicating a role for 
DGKs in t10, c12 CLA signaling is based on the use of a chemical inhibitor, which may 
not be specific to the target of interest. Therefor, it will be important to knockdown 
candidate DGK isoforms to confirm their role in t10,c12 CLA-mediated inflammatory 
signaling and insulin resistance.   
Q2. What role does PLC play in t10,c12 CLA-mediated inflammation? 
We have previously published data showing that D609, a PLC inhibitor, 
attenuated intracellular calcium levels, reactive oxygen species (ROS) production, and 
inflammatory gene expression induced by t10,c12 CLA. This inhibitor has been reported 
to be specific for phosphatidylcholine (PC)-PLC. However, other PLCs like 
phosphatidylinositol 4,5-bisphosphate (PIP2)-PLC may also be involved in regulating 
intracellular calcium levels via inositol 3-phosphate (IP3)-mediated endoplasmic 
reticulum (ER) calcium mobilization. Therefore, future studies will be conducted using 
the chemical inhibitor U73122, which targets PIP2-PLC. Activation of candidate PLC 
isoforms will be measured by determining their phosphorylation status with t10,c12 CLA 
treatment in primary human adipocytes. Once a candid te PLC isoform is identified, 
siRNA will be used to knockdown the gene to confirm ts role in regulating t10,c12 CLA-
mediated inflammation and insulin resistance.  
Q3. Is t10,c12 CLA-mediated inflammatory signaling dependent on GPCR 
activation? 
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We have previously shown that pertussis toxin (PTX), a general GPCR inhibitor, 
attenuates t10,c12 CLA-mediated MEK/ERK phosphorylation and suppression of 
insulin-stimulated glucose uptake. Furthermore, data generated from our lab in the past 5 
years strongly suggest that t10,c12 CLA activates a GPCR, as calcium levels are elevated 
and chemical inhibition of proteins involved in calium signaling, like PLC, DGK, and 
calcium/calmodulin-dependent protein kinase (CaMK)II attenuates t10,c12 CLA 
signaling. Therefore, future studies will be conducted to determine the GPCRs potentially 
activated by t10,c12 CLA. Microarray data generated in our lab by Dr. Arion Kennedy 
will be analyzed to determine the GPCRs expressed in our cultures of primary human 
adipocytes, and subsequently confirmed using TaqMan assays from Applied Biosystems. 
In addition, a GPR40 inhibitor will be obtained from Dr. C. Jayawickreme at 
GlaxoSmithCline, RTP, NC to determine its role in t10,c12 CLA-mediated inflammatory 
signaling and insulin resistance. Interestingly, we have preliminary data showing that a 
GPR120 agonist, which has been shown to antagonize GPR40 signaling, dose-
dependently attenuates t10,c12 CLA-induced inflammatory gene expression (data not 
shown). Lastly, candidate GPCRs will be knocked down using siRNA to determine their 
involvement in elevated intracellular calcium levels, inflammatory gene expression, 
insulin resistance, and delipidation.  
In summary, further research is needed to better understand the upstream 
mechanisms responsible for t10,c12 CLA-mediated inflammation, insulin resistance, and 
delipidation. The proposed studies will provide further insight into the t10,c12 CLA’s 
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mechanism of action, which will be important for evaluating the efficacy, specificity, and 
potential side effects of CLA consumption for use a a weight loss agent. 
 
 
